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Abstract  
Prostate cancer growth is androgen dependent, but can bypass treatments inhibiting androgen 
production and continues to grow, probably utilising the adrenal alternative dihydrotestosterone 
(DHT) biosynthesis pathway. In contrast, the role of steroids in ovarian cancer is not clearly 
defined, although it is known that progesterone and oestrogens affect this cancer proliferation. 
The thesis aims were to investigate steroid relation with prostate and ovarian cancers as well as 
characterise three adrenocortical carcinoma cell (ACC) lines derived from H295 cell line.   
The steroidogenesis characterisation of three ACC cell line strains indicated that they have 
similar steroidogenic capability to the native adrenal cortex. Another ACC cell line, H295R1, 
was used to investigate whether CYP17A1, a key enzyme in androgen synthesis, inhibition was 
sufficient to cause a shift towards the alternative DHT biosynthesis pathway. Although 
knockdown was achieved and affected steroidogenesis, no shift towards the alternative pathway  
was demonstrated.                                                                    .   
The ovarian cancer cell lines, A2780, COV434, CaOv-3 and OAW42, showed steroidogenic 
capabilities suggesting that the tumours are probably transformed with steroidogenic capability. 
The results obtained indicate that the adrenal gland might have a role in prostate cancer 
resistance to treatment. They also demonstrate that ovarian cancer might be steroid-producing 
and/or dependent.  
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1.0 General Introduction  
 
Steroids are cholesterol-derived hormones essential for pre- and postnatal body function and 
development (Miller and Auchus, 2011), such as salt regulation, the inflammatory response, 
glucose metabolism, sex and brain development, pregnancy and lactation. Steroid hormones 
are all based on a 4-ring structure and all derived from cholesterol (Figure 1-1). They differ by 
the location of the double bond, which is either in ring A between carbon four and five (Δ4) or 
in ring B between carbon five and six (Δ5), and in the position of hydroxylation or redox 
modifications. The steroid hormones are mainly synthesised in the adrenal glands, in the cortex, 
that synthesises mineralocorticoids, glucocorticoids and androgen precursors, and in the 
gonads, that synthesise the sex hormones, androgens and oestrogens. The above hormones are 
synthesised in a multi-enzyme process called steroidogenesis. The steroidogenic enzymes 
synthesising the hormones are divided into two main groups, cytochrome P450 (CYP) enzymes, 
catalysing oxidative reactions, which are mostly irreversible (Miller and Auchus, 2011), and 
the hydroxysteroid dehydrogenase (HSD) enzymes catalyse redox reactions, which are mostly 
reversible (Miller and Auchus, 2011). 
De novo steroid synthesis, accruing in the adrenal glands and gonads, starts when cholesterol is 
imported into the mitochondrion by steroidogenic acute regulatory protein (StAR), where the 
side-chain cleavage enzyme (CYP11A1) catalyses the synthesis of the first steroid, 
pregnenolone, by removing the side-chain at carbon 22, and carboxylation of carbon 20.  
 
In this thesis, I will focus on adrenal and ovarian steroidogenesis. 
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Figure 1-1: Cholesterol structure  
The chemical structure of cholesterol with carbon numbers and ring identification is shown. The steroid hormones are based 
on this 4-ring cholesterol structure.  Drawn with BIOVIA draw by Accelrys. 
 
1.1 Adrenal Anatomy and Steroidogenesis 
The adrenal glands are positioned above each kidney, and are the main source of steroids in the 
body. Each adrenal gland has two functional sections, the medulla that synthesises 
catecholamines, which will not be further discussed, and the cortex which synthesises steroid 
hormones (Figure 1-2 A). The cortex contains three sections known as zones, the outer layer, 
zona glomerulusa, which synthesises mineralocorticoids; the middle layer, zona fasciculata, 
which synthesises glucocorticoids and the inner layer, zona reticularis, which synthesises 
androgens (Figure 1-2 B). The synthesis of the glucocorticoids and androgens is regulated by 
the hypothalamic-pituitary-adrenal (HPA) axis, while the mineralocorticoids are regulated by 
the kidney through renin secretion and fluctuations in renal blood pressure.  
The compartmentalisation of steroidogenesis in the adrenal cortex is achieved by enzyme 
expression patterns (Rainey, 1999, Rainey et al., 2002, Vinson, 2003, Nguyen and Conley, 
2008). The zona glomerulosa does not express CYP17A1, preventing synthesis of any other 
steroid group other than mineralocorticoids (Miller and Auchus, 2011). The zona fasciculata, 
that synthesises glucocorticoids, expresses only CYP11B1, thereby preventing the conversion 
of corticosterone to aldosterone (Miller and Auchus, 2011, Pascoe et al., 1995, Rainey, 1999). 
The zona reticularis expresses the co-factor cytochrome b5 which is required for the 17,20-
lyase activity of CYP17A1 (Rainey and Nakamura, 2008), and expresses little CYP21A2 and 
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CYP11B enzymes, therefore, synthesises only androgen precursors, and does not synthesise 
gluco- or mineralocorticoids.  
 
 
 
 
 
 
Figure 1-2: The adrenal gland and cortex 
A. The adrenal gland has a triangular shape, and contains three layers: a capsule, surrounding the gland, and the two 
functional sections the cortex and medulla, which produce steroids and catecholamines respectively. B. A cross-section of  
the adrenal gland, showing the different layers, capsule that surrounds it, the three zones of the cortex and the medulla.  
 
Two key enzymes are involved in the steroidogenesis process determining the steroid route 
(3βHSD2) or family (CYP17A1) to be synthesised (Figure 1-3). The 3βHSD2, catalyses the 
shift between Δ5 and Δ4 (Andersen and Ezcurra, 2014, Simard et al., 2005), and is a bi-
functional enzyme catalysing 3β-hydrogenation followed by 5 to 4 isomerization (Simard et al., 
2005). It catalyses its five substrates, pregnenolone, 17α-hydroxypregnenolone (17OHPreg), 
dehydroepiandrosterone (DHEA) and androstenediol with the same efficiency (Lee et al., 1999, 
Miller and Auchus, 2011), and the products are the respective 4-ketosteroids, progesterone, 
17α-hydroxyprogesterone (17OHP), androstenedione and testosterone (Simard et al., 2005). 
The affinity of 3βHSD2 for pregnenolone is much lower than of CYP17A1 (Km 5µM vs. 
0.8µM respectively), favouring the Δ5 route (Miller and Auchus, 2011, Auchus et al., 1998). 
Nevertheless, the ratio between 3βHSD2 and CYP17A1 also plays a role in the determination 
as to which route, Δ5 or Δ4, will dominate. 
CAPSULE 
A B 
CORTEX 
MEDULLA 
Medulla 
Zona glomerulosa– mineralocorticoids 
Capsule 
Zona fasciculata –  glucocorticoids  
Zona reticularis –  androgens 
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 CYP17A1 is an important bi-functional enzyme, catalysing the conversion of progestins to 
androgens. In the adrenal glands, it is located in the zona fasciculata and zona reticularis (Miller 
and Auchus, 2011, Suzuki et al., 2000) and in the ovaries it is located in the theca cells and in 
the extra-follicular parts of the ovaries (Smyth et al., 1993), although weak hydroxylation 
activity can be detected in granulosa cells (Moon et al., 1978, Tsang et al., 1980). CYP17A1 
function depends on the electron transferase P450 oxidoreductase (POR) (Pandey and Miller, 
2005, Auchus et al., 1998), which is also required for the function of other CYP enzymes such 
as CYP21A2 and CYP19A1 (Miller and Auchus, 2011, Pandey and Miller, 2005). The two 
functions of CYP17A1 enzyme, 17α-hydroxylation and 17,20-lyase activity, are performed in 
the same active site, and the modulation is post-transcriptional, by phosphorylation or with 
cytochrome b5 that supports the lyase activity (Pandey and Miller, 2005, Auchus et al., 1998). 
CYP17A1 low affinity towards 17OHP (Miller and Auchus, 2011, Auchus et al., 1998), 
prevents direct Δ4 androgen synthesis. Therefore, androstenedione and testosterone are 
synthesised through 3βHSD from DHEA and androstenediol.  
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Figure 1-3: The adrenal steroidogenesis 
The three groups of steroids, mineralocorticoids (purple), glucocorticoids (blue) and androgens (red) are synthesised in the 
adrenal cortex. Each group is synthesised in a different zone the zona glomerulosa, fasciculata and reticularis respectively.  
POR – P450 oxidoreductase, an electron transferase is required for CYP17A1 and CYP21A2 enzyme activity. 
OH – hydroxy, DHEA – dehydroepiandrosterone.  Adapted from J. Hofland 
1.1.1 Mineralocorticoids  
Mineralocorticoids, 21 carbon steroids, regulate salt and water balance in the body, affecting 
blood pressure. The mineralocorticoids, of which aldosterone is the most potent, act through a 
nuclear receptor, mineralocorticoid receptor (MR) (Williams and Williams, 2003, Nakamura et 
al., 2015), and mediate sodium/potassium adenosine tri-phosphate (ATPase) pumps in the 
kidney, resulting in an increase of sodium intake into the kidney’s nephron in exchange for 
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potassium, followed by an increase in water osmosis (Williams and Williams, 2003, Booth et 
al., 2002). This results in an increase in extra-cellular fluid and elevates the blood pressure 
(Williams and Williams, 2003, Booth et al., 2002). Mineralocorticoid synthesis occurs in the 
zona glomerulosa, where pregnenolone is converted to progesterone by 3βHSD2, and then is 
21-hydroxylased to deoxycorticosterone (DOC) by CYP21A2. The last two stages are 
performed by CYP11B enzymes, CYP11B1 converts DOC to corticosterone and CYP11B2 
converts it to aldosterone (Lisurek and Bernhardt, 2004, Suzuki et al., 2000) (Figure 1-3 
Purple). Aldosterone synthesis is regulated through the renin-angiotensin system, and their 
secretion is affected by potassium concentrations (Clark et al., 1995, Nakamura et al., 2015, 
Quinn and Williams, 1988). Regulation may also include involvement of adrenocorticotropic 
hormone (ACTH) (GalloPayet et al., 1996, Quinn and Williams, 1988). Although aldosterone 
is the main mineralocorticoid, DOC and corticosterone also have mineralocorticoid activity 
(Williams and Williams, 2003, Sheppard and Funder, 1987). 
1.1.2 Glucocorticoids 
Glucocorticoids, 21 carbon steroids, are involved in many physiological functions including: 
energy metabolism – glucose regulation, cell function, reproduction, inflammation (Odermatt 
and Klusonova, 2015), birth (Liggins, 1994) and brain function (Miller, 2015) and are crucial 
for human survival, as they control glucose distribution in stress conditions. The 
glucocorticoids, primarily cortisol, are known as stress hormones, since stress increases their 
secretion, through the HPA axis (Sapolsky et al., 2000). They are synthesised in the middle 
zone of the cortex, the zona fasciculata. Pregnenolone is converted to 17OHP by 3βHSD2 and 
CYP17A1. The lack of cytochrome b5 in the zona fasciculata inhibits the 17,20-lyase activity 
of CYP17A1 thus preventing androgen synthesis (Suzuki et al., 2000, Miller and Auchus, 
2011). CYP21A1 then converts the steroid to 11-deoxycortisol that is in turn converted to 
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cortisol by CYP11B1 (Figure 1-3 Blue). They affect their target cells through a nuclear receptor, 
glucocorticoid receptor (GR). 
1.1.3 Androgen Synthesis 
Androgens, 19 carbon steroids, are known as the male sex hormones, although they also affect 
females (Walters, 2015). Through androgen aromatisation, they are oestrogen precursors 
(Leung and Armstrong, 1980), and are needed for the normal development of oocytes 
(Hellbaum et al., 1956, Prizant et al., 2014, Walters et al., 2008). They are responsible for the 
manifestation of secondary sex characteristics, external genitalia development, muscle growth 
and brain development. In males, androgens have proliferative effects on prostate cells, which 
continue in prostate tumours and also in castration resistant prostate cancer (CRPC) (Tan et al., 
2015, Heinlein and Chang, 2004, Ang et al., 2009). Androgens are synthesised in the adrenal 
glands and in the gonads. In the adrenal gland the synthesis takes place in the zona reticularis. 
In the ovaries androgens are synthesised in the theca cells, ending in androstenedione and 
testosterone (Abraham, 1974). In males, the testis synthesises steroids, mostly testosterone and 
dihydrotestosterone (DHT) de novo.  
In females, about half of the androstenedione and testosterone is synthesised in the ovaries 
(Abraham, 1974, Judd and Yen, 1973), throughout the menstrual cycle, and their levels 
fluctuate with a peak during the luteinizing hormone (LH) surge (Abraham, 1974). Androgens 
affect their target cells via a nuclear receptor, androgen receptor (AR), that can be found in the 
theca and granulosa cells, indicating that androgens have a role in follicular development, as 
reviewed by Prizant et al. (2014) and Walters et al. (2008), and as can be seen in 
hyperandrogenism that causes polycystic ovaries. In this condition follicular development 
arrests before maturation, and there is accumulation of arrested follicles (Magoffin, 2002). It is 
noteworthy that most of the data concerning the androgens and the ovaries is derived from 
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animal studies and therefore their effects in women are not fully known. In the adrenal glands 
androgens can be synthesised by at least three pathways, and this multi-pathway synthesis might 
have a role in the development of prostate cancer resistance to the current treatments or other 
conditions evolved from androgen excess. The pathways will be presented in the following 
three sections.  
1.1.3.1 Classic Pathway 
The first androgen synthesised in this pathway is DHEA, which is converted from 17OHPreg 
by CYP17A1. DHEA can be converted to two other androgens, androstenedione and 
androstenediol, but probably due to enzyme specificity, is converted mostly to androstenedione 
(Miller and Auchus, 2011, Lasley et al., 2013). No direct comparison could be found in the 
literature comparing their enzyme synthesis pathways. In the adrenal, the synthesis terminates 
with DHEA and androstenedione that are secreted into the circulation (Abraham, 1974). Some 
testosterone and DHT are also secreted by the adrenal gland (Abraham, 1974). The ovary 
synthesises androgens, androstenedione and testosterone de novo in the theca cells (Abraham, 
1974, Tsang et al., 1980), but most are aromatised to oestrogens, and a small amount is secreted 
into the circulation (Abraham, 1974, Smith and Ryan, 1961, Miller and Auchus, 2011). In the 
male, the testis synthesises DHT from testosterone by 5α-reductase type 1 (Miller and Auchus, 
2011), while in the prostate gland DHT is synthesised from androstanedione (Luu-The et al., 
2008). Moreover, in studies performed to understand how prostate cancer becomes resistante 
to treatment it has been shown that DHT is synthesised through androstenedione rather than 
testosterone (Mohler et al., 2011, Chang et al., 2011) (Figure 1-3 Red). 
1.1.3.2 Alternative Androgen Synthesis Pathway 
This pathway was first described in 2003 by Wilson and colleagues (Wilson et al., 2003) in the 
tammar wallaby pouch young, and describes synthesis of DHT through androsterone (Wilson 
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et al., 2003, Arlt et al., 2004, Auchus, 2004) and not testosterone (Figure 1-4). According to 
Wilson, 17OHP is reduced by 5α-reductase to 5α-pregnan-17-ol-3,20-dione, that is then 
converted to 17-hydroxy-5α-pregnan-3α-ol-20one (17-OH-allopregnanolone) by 3βHSD and 
to androsterone by CYP17A1. Androsterone can be converted to DHT either through 
androstanediol or androstanedione. This pathway also functions in humans suffering from 
abnormalities in steroidogenesis (Miller and Auchus, 2011, Arlt et al., 2004, Turcu and Auchus, 
2015). Children with the severe form of POR deficiency, a condition where P450 
oxidoreductase, an electron transferase, which is needed for the correct function of CYP17A1 
and CYP21A2, is mutant and not functioning, do not present the equivalent phenotype (Arlt et 
al., 2004), indicating that those patients bypass the block created by the lack of POR. 
Furthermore, these patients synthesise androgens through the alternative pathway, as delineated 
in the tammar wallaby (Arlt et al., 2004). Later, Attard and colleagues (Attard et al., 2012) 
demonstrated that this pathway is activated in adult patients treated with abiraterone against 
prostate cancer. Their results also showed that this pathway might be active in the adrenal gland. 
Although this pathway is considered to be an alternative it has been found that the metabolites 
of progesterone and 17OHP, allopregnanolone and 17-OH-allopregnanolone respectively are 
better CYP17A1 substrates than the “classic” steroids, namely, pregnenolone, progesterone and 
their 17α-hydroxylase forms (Gupta et al., 2003). Moreover, 17-OH-allopregnanolone is the 
most efficient 17,20-lyase substrate (Gupta et al., 2003). This high affinity of CYP17A1 to the 
alternative androgens means that even under inhibition the residual enzymatic activity is enough 
to metabolise steroids downstream to CYP17A1 that can then be metabolised to DHT.     
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Figure 1-4: Alternative DHT synthesis pathway 
In the zona reticularis of the adrenal gland DHT can be synthesised in an alternative pathway, shown here in blue. This 
pathway was discovered in 2003 (Wilson et al., 2003), and in humans it is active in pathological conditions. This pathway 
enables androgen synthesis even if CYP17A1 function is impaired, due to the high affinity of CYP17A1 to the alternative 
steroids, mostly to 17-OH-allopregnanolone. 17-OH-allopregnenalone is the most efficient 17,20-lyase substrate. DHT – 
dihydrotestosterone, OH – hydroxy. Adapted from J. Hofland  
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1.1.3.3 11β-Hydroxyandrostenedione Pathway 
This pathway has been known for several decades (Bloch et al., 1957, Chang et al., 1963) but 
only recently recognised as an important source for adrenal androgens. Its products are secreted 
in higher levels than androstenedione (Schloms et al., 2012, Rege et al., 2013, Xing et al., 
2011). In this pathway, CYP11B1 catalyses the hydroxylation of androstenedione to  
11-hydroxyandrostenedione (11OHA4) (Schloms et al., 2012), a precursor for the active 
androgens 11-ketotestosterone and 11-hydroxyDHT (Figure 1-5) (Storbeck et al., 2013, Swart 
et al., 2013). This pathway was recently reviewed by Bloem (Bloem et al., 2013) and Swart 
(Swart and Storbeck, 2015), but is not discussed further here, and its products were not analysed 
in this dissertation.  
 
 
 
 
1.2 The Ovary 
The ovaries are the female gonads and are located in the abdominal cavity, on either side of the 
uterus, below the Fallopian tubes. They are loosely connected to the uterine wall by peritoneal 
ligaments. The ovaries are constituted of two functional areas; the medulla which contains the 
blood vessels and the cortex which holds the follicles. There are four types of cells: germ, 
Figure 1-5: 11β-Hydroxyandrostenedione Pathway 
Androstenedione is converted to 11-OH-androstendione, which can be converted to two active 11-keto androgens,  
11-ketotestosterone and 11-ketoDHT. This pathway occurs only in the adrenal gland. 
DHT – dihydrotestosterone, OH – hydroxy Adapted from J. Hofland 
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connective tissue, steroid producing and supporting cells. The latter three are somatic. The 
ovaries have a dual function, oocyte storage and assistance in their maturation, and during fertile 
years, synthesis and secretion of oestrogens. After ovulation, in the expectation of pregnancy 
the ovaries also secrete progesterone. The ovaries can synthesise oestrogens de novo or from 
androgen precursors derived from the adrenal gland. Ovarian steroidogenesis occurs mainly in 
the follicle cells surrounding the oocyte, the theca and the granulosa cells. The ovarian steroid 
levels change according to the menstrual cycle and the process is regulated by the 
hypothalamic-pituitary-gonadal axis. The steroidogenesis is considered to be divided between 
the two cell types of the follicle, in what is known as the two cells - two gonadotropin theory 
(Ryan and Petro, 1966, Ryan et al., 1968, Hillier et al., 1994, Short, 1962). According to this 
theory, luteinizing hormone (LH) regulates androgen synthesis in the theca cells and follicle-
stimulating hormone (FSH) regulates the granulosa cells (Howles, 2000, Havelock et al., 2004, 
Meinhardt and Mullis, 2002). Gonadotropin releasing hormone (GnRH) is secreted from the 
hypothalamus stimulating secretion of the glycoprotein hormones LH and FSH from the 
anterior pituitary gland. The effects of LH and FSH are mediated through cyclic adenosine 
monophosphate (cAMP) (Conti, 2002), LH mediates CYP11A1 and aromatase activities 
(Andersen and Ezcurra, 2014), and androgen synthesis in theca cells (Fevold, 1941, Greep et 
al., 1942). FSH, as its name implies, facilitates follicle growth (Fevold, 1941, Greep et al., 
1942), and it also mediates androgens, diffused from the theca cells, conversion to oestrogens 
in the granulosa cells aided by LH receptor expression (Andersen and Ezcurra, 2014, 
Wimalasena et al., 1991). Following ovulation, the granulosa cells of the follicle commence to 
secretion progesterone under the influence of human chorionic gonadotropin, an equivalent of 
LH (Figure 1-6). 
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Figure 1-6: Ovarian steroidogenesis 
Ovarian steroidogenesis takes place in the cells surrounding the oocyte: theca and granulosa cells. According to the two cells- 
two gonadotropin theory, theca cells synthesise androgens under the influence of luteinising hormone (LH) and the granulosa 
cells convert them to oestrogen under follicular stimulating hormone (FSH) regulation. The upper panel describes the 
steroidogenesis in the growing follicle, while the lower panel describes the steroidogenesis in the corpus luteum. DHEA – 
dehydroepiandrosterone, cAMP – cyclic adenosine mono phosphate, OH – hydroxy.  
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1.2.1 Progestins  
Progestins are 21 carbon steroids that serve as precursors for all the other steroids. Their name 
is derived from the combination of pro and gestation (pregnancy), as the main steroid in this 
group progesterone is vital for pregnancy support. The progestins and their 17-hydroxy forms 
are not active steroids and only serve as precursors, with the exception of progesterone. In the 
adrenal gland progestins are synthesised only as precursors, whereas, in the corpus luteum, 
progesterone is synthesised in the granulosa cells (Figure 1-6, lower panel). Progesterone is the 
first functional hormone to be synthesised in the ovary, prepares the body for pregnancy, has a 
role in the prevention of ovarian cancer (Diep et al., 2015), serving as anti-proliferative (Yu et 
al., 2001, Syed et al., 2001, Keith Bechtel and Bonavida, 2001, Bu et al., 1997) and improving 
survival in a dose dependent manner (Sieh et al., 2013, Yu et al., 2001). It is metabolised 
directly from pregnenolone by 3βHSD2, and as described before, can be 17α-hydroxylated to 
17OHP. Since 17,20-lyase has low affinity towards 17OHP the Δ5 pathway does not continue 
on to produce androgens (Andersen and Ezcurra, 2014). Progesterone secretion fluctuates 
during the menstrual cycle, being low in the beginning of the cycle and increases after the LH 
surge, about mid cycle (Abraham, 1974), during the luteal phase. Progesterone acts through a 
receptor, progesterone receptor (PR). There are two types of PR: type A (PR-A) is essential for 
ovarian function and its level decreases in ovarian cancer (Diep et al., 2015), and type B (PR-
B), which on the other hand increases in ovarian cancer, and indicates a favourable prognosis 
(Diep et al., 2015). 
1.2.2 Oestrogens 
Oestrogens, 18 carbon steroids, are the main female sex hormones, and have a crucial role in 
female and male fertility (Stocco, 2008). Oestradiol is the most potent oestrogen in the female 
body and most of the data described here refers to it. Oestrogens are responsible for the 
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development of secondary sex characteristics in females, including pubic hair, breast 
development, the menstrual cycle and the preparation of the female body for pregnancy and 
birth. They also affect brain function (Hara et al., 2015, Kim et al., 2015, Nelson and Bulun, 
2001). The oestrogens, oestrone and oestradiol, are synthesised in the ovaries, within the 
granulosa cells under the regulation of FSH, or in target tissues, such as the breast, via 
aromatisation of the A ring of either androstenedione or testosterone. The androstenedione 
synthesised in the theca cells diffuses to the granulosa cells and is converted to oestrone, the 
least potent oestrogen. The minority of the androstenedione is converted by 17βHSD3 to 
testosterone, which is then aromatised to the most potent oestrogen, oestradiol. Oestradiol can 
also be synthesised from oestrone by 17βHSD1 (Miller and Auchus, 2011). The oestradiol 
levels vary during the menstrual cycle, being secreted mostly in the follicular phase (Abraham, 
1974, Miller and Auchus, 2011), and decreases after the LH surge (Abraham, 1974). Oestriol 
levels are very low except during pregnancy. GnRH and aromatase (CYP19A1) regulate 
oestrogen synthesis, the former in the ovarian and brain production (Prange-Kiel et al., 2013), 
and the latter in the peripheral tissues (Simpson, 2003). The role of ovarian oestrogens in 
ovarian cancer (OC) is not clear. While one study suggests they have protective effect, as they 
decrease cell proliferation (Wimalasena et al., 1992), another suggests the opposite (Li et al., 
2014). 
1.3 Steroids and Cancer 
1.3.1 Steroid Producing Cancer – Adrenocortical Carcinoma  
Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal gland cortex. It affects 
0.72 per million people in the USA (Else et al., 2014, Allolio and Fassnacht, 2006) with a low 
survival rate (Kebebew et al., 2006, Allolio and Fassnacht, 2006). Adrenocortical carcinoma 
affects females at higher rates than males, and there are two peaks, that accord in both genders: 
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in childhood and adults in their 40s and 50s (Allolio and Fassnacht, 2006, Wajchenberg et al., 
2000, Wooten and King, 1993, Else et al., 2014, Luton et al., 1990). Most patients present with 
syndromes of adrenal hormone excess, either clinically or biochemically (Else et al., 2014, 
Allolio and Fassnacht, 2006). Functional ACC is mostly detected in children and women (Else 
et al., 2014, Wooten and King, 1993), and the functionality of the tumour correlates with 
adrenal steroidogenesis. Excess glucocorticoids will result in rapidly progressing Cushing’s 
syndrome sometimes with virilisation. In women, androgen excess will result in virilisation, 
male pattern balding and deepening of the voice. The male equivalent is gynaecomastia and 
testicular atrophy in oestrogen secreting ACC (Else et al., 2014, Luton et al., 1990). A third of 
the ACC cases present with tumour symptoms such as abdominal pain, weight loss and 
weakness (Luton et al., 1990, Else et al., 2014). A relatively large percentage of cases, up to 
30%, are detected accidentally, during scans for unrelated conditions, known as incidentalomas 
(Else et al., 2014, Kebebew et al., 2006). The diagnosis of ACC is based on biochemistry, 
hormone level measurements, imaging using computerised tomography, magnetic resonance, 
positron emission tomography or ultrasound as well as pathology (Else et al., 2014, Allolio and 
Fassnacht, 2006, Fassnacht et al., 2004, Wajchenberg et al., 2000). Biochemical analysis 
includes measurements of ACTH, which is supressed, cortisol which is elevated, and a 
dexamethasone suppression test based on the Cushing’s test (Nieman et al., 2008, Else et al., 
2014). Elevated aldosterone plasma levels and plasma renin activity will indicate the 
involvement of the zona glomerulosa in the ACC (Else et al., 2014, Allolio and Fassnacht, 
2006). Since not all ACCs are functional, biochemistry analysis might not be sufficient to detect 
an ACC tumour, and therefore the diagnosis is also based on imaging (Else et al., 2014). Image 
detection is based on the size and texture of the tumour (Else et al., 2014). Adrenocortical 
carcinoma tumours are usually large, with necrosis and haemorrhage (Allolio and Fassnacht, 
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2006, Else et al., 2014). The treatment includes surgery, radiotherapy and chemotherapy. In 
some cases, mitotane is given alone or as an adjuvant with the other modalities, mostly with 
surgery (Else et al., 2014, Allolio and Fassnacht, 2006, Luton et al., 1990, Wajchenberg et al., 
2000).  
1.3.2 Steroid Dependent Cancer – Prostate Cancer  
The prostate is an exocrine gland and part of the male reproductive system. Its physiological 
role is to help to create the semen by adding fluid to the sperm originated in the testis. It has no 
functional equivalent in female. The gland is located within the pelvis, below the bladder. The 
prostatic epithelial and stromal cells are androgen sensitive and depend on them for their 
growth. Due to the long-term exposure to androgen in the male, the prostate gland increases in 
size with age. Prostate cancer (PC) is the most prevalent cancer in men (Siegel et al., 2015, 
Cancer Research UK, 2014a), and the second most common cause of cancer-related death in 
men (Siegel et al., 2015, Cancer Research UK, 2014b). It affects mostly men over 50 years and 
the risk increases with age. The cancer development is divided into four stages, I-IV. Stages I 
and II are localised to the gland, and in the last two stages (III and IV) the cancer invades other 
organs. In stage III nearby organs or lymph nodes are invaded and in stage IV the cancer 
metastasises to remote organs. Each step has a subdivision allowing for a finer description of 
the tumour (American Cancer Society, 2015a), and PC survival rates vary according to the stage 
of detection; in the early stages, local and regional, the five-year survival rates approach 100%, 
while in the advanced stages the five-year survival drops to about 30% (Siegel et al., 2015, 
SEER program, 2014). The cancer is androgen dependent, utilizing adrenal and gonadal 
androgens to grow. Therefore, the first line of treatment is to deprive the tumour of androgens. 
The treatment strategy changes according to the stage. In the early stages, when the tumour is 
localised to the gland, some patients could choose non-active treatment, essentially wait, watch 
 30 
 
and see [NICE (National Institute for Health and Care Excellence), 2014a, American Cancer 
Society, 2015b]. If an active treatment is chosen, the patient can choose to undergo a radical 
prostatectomy. If the tumour is not localised the first line of treatment is androgen deprivation 
(American Cancer Society, 2015b, NICE, 2014b), either surgically or pharmacologically, 
including orchidectomy, GnRH (agonist or antagonist) or other anti-androgen treatment. 
Treatment might also involve radio- or chemotherapy. 
In later stages the treatment is not curative and most men will progress towards castration 
resistant PC (CRPC) after two to five years (Nussbaum et al., 2016, Leibowitz-Amit and 
Joshua, 2012, Harshman and Taplin, 2013), and most will die within three years after CRPC is 
detected (Nussbaum et al., 2016). Nevertheless, during the responsive period 70-80% of 
patients will benefit from the androgen deprivation treatment, resulting in reduction of 
symptoms, tumour regression and a decrease in prostate specific antigen (PSA) that serves as a 
biomarker (Damber and Aus, 2008, de Bono et al., 2011). Although CRPC continues to grow 
despite low androgen levels, it is still androgen dependent (Attard et al., 2008, Ang et al., 2009). 
The resistance to the androgen ablation in the body is achieved by one or more of several 
mechanisms (Friedlander and Ryan, 2012, Karantanos et al., 2013, Agarwal et al., 2014, Egan 
et al., 2014). Interestingly, intra-tumoural androgen concentrations within the CRPC are similar 
to the concentrations before ablation (Titus et al., 2005), indicating intra-tumoural androgen 
synthesis (Ning et al., 2013, Yin et al., 2013), and these levels allow for androgen receptor 
(AR) activation. To counter the CRPC resulting from residual intra-tumoural androgens, gain 
of promiscuous AR function or AR overexpression, two new hormonal therapies were approved 
by the Food and Drug Administration in the last few years (Harshman and Taplin, 2013, Ning 
et al., 2013, Yin et al., 2013). These are enzalutamide, an AR antagonist and abiraterone, a 
cytochrome P450 (CYP) 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor (Tan and Haaland, 
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2014). Abiraterone is a selective steroidal CYP17A inhibitor, derived from pregnenolone 
(Ferraldeschi et al., 2013). It was approved in the treatment for metastatic CRPC before and 
after chemotherapy (Kluetz et al., 2013, Thompson, 2011). The targeting of CYP17A1 is 
derived from the importance of the enzyme in the androgen biosynthesis pathway. It is a key 
enzyme in the synthesis process catalysing two steps, as described above. Theoretically, 
CYP17A1 inhibition should result in complete androgen abolition. Abiraterone is not 17,20-
lyase selective and therefore results in cortisol inhibition and mineralocorticoid increase (Attard 
et al., 2012, Ryan et al., 2010). The treatment is not curative, although it has a beneficial effect 
on overall survival of four to five months on average (de Bono et al., 2011).  
1.3.3 Ovarian Cancer 
Ovarian cancer (OC) is the 7th most common and 7th most lethal cancer in women worldwide 
(Ferlay et al., 2010, Prat and Oncology, 2014). However, in the USA and Europe it is first and 
fifth most common cancer in women, respectively (Siegel et al., 2015, Ferlay et al., 2010, Prat 
and Oncology, 2014) and second and sixth most lethal cancer, respectively (Siegel et al., 2015). 
Furthermore, OC is the most lethal female reproductive tract cancer (Cho and Shih Ie, 2009). 
Its five-year survival rate is low and stands at around 45% (Siegel et al., 2015), although 
treatments have improved over the years. Survival rates vary according to the detection stage; 
the earlier the detection the better the prognosis and yet most cases are diagnosed only after the 
tumour has breached the ovary (79%) (SEER program, 2011).  
 
Ovarian cancer has no distinctive symptoms and signs. The symptoms, include but not limited 
to, abdominal or back pain, abdominal bloating and nausea, which could have easily resulted 
from other conditions, and are only distinguished by the intensity and the duration of the 
symptoms. The effect of the lack of specific markers can be seen from the statistics. The earliest 
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stage, while the tumour is localised, has the highest five-year survival rate, but it accounts for 
only 15% of the cases. The regional stage accounts for 18% of cases, with about 72% five-year 
survival rate. The distant (metastatic disease) stage accounts for about 60% of cases but has the 
poorest survival rate of about 27% (Howlader N, 2014, SEER program, 2011). The late 
detection is partially due to the lack of biomarkers as symptoms and signs cannot be relied 
upon. Treatment options include surgery and chemotherapy. Women harbouring a BRCA gene 
mutation, have a higher lifetime risk of developing breast and/or ovarian cancer and are 
encouraged to have prophylactic mastectomy and/or uni- bilateral salpingo-oophorectomy, the 
removal of Fallopian tubes and ovaries. Those women are often diagnosed with Fallopian tube 
cancer while the ovaries are unremarkable (Callahan et al., 2007, Finch et al., 2006).  
The progression of the cancer is divided into stages (Mutch and Prat, 2014, Prat and Oncology, 
2014) according to locale spread, is further sub-divided based of various histological features 
(Mutch and Prat, 2014, Prat and Oncology, 2014, Meinhold-Heerlein et al., 2016).  
 Stage I – The tumour is uni- or bilateral and confined to the ovary.  
 Stage II – The tumour (uni- or bilateral) has breached the ovary but is confined to the     
            pelvis. Cancer cells might be floating in the peritoneal cavity. 
 Stage III – A uni- bilateral tumour that has spread outside the pelvis or to the lymph      
            nodes.  
 Stage IV – Tumour has metastasised to areas other than the peritoneum.  
The ovarian cancer combines several distinct tumour types, each with unique clinical and 
pathological characteristics. They belong to three groups, with epithelial malignancies 
accounting for about 90%, malignant germ cell tumours account for about 3%, and malignant 
sex cord-stromal tumours for 1-2% (Mutch and Prat, 2014, Prat and Oncology, 2014)  
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(Figure 1-7 A). The division is mainly histological, and there is a therapeutic importance for 
correct identification and staging of the tumour (Prat and Oncology, 2014). The division is 
based on tumour cell origin and morphology (Cho and Shih Ie, 2009, Prat, 2012, Gilks and Prat, 
2009), and today there are attempts to use genetics to identify the different tumour types 
(Domcke et al., 2013, Anglesio et al., 2013, Horlings et al., 2015). Although the tumours may 
present in the ovaries, the gathered body of evidence indicates that not all are of primary ovarian 
origin. 
 Epithelial malignancies are the most common OC (Cho and Shih Ie, 2009, Gilks and Prat, 
2009, Mutch and Prat, 2014), and are divided to five sub-types, according to morphology, 
histology, molecular features and genetics (Gilks and Prat, 2009, Cho and Shih Ie, 2009, Prat, 
2012, Jayson et al., 2014, Mutch and Prat, 2014) (Figure 1-7 B). Albeit grouped under the same 
title, these sub-types are in fact different diseases (Prat, 2012, Mutch and Prat, 2014, Gilks and 
Prat, 2009).  
 
 
 
 
 
 
 
 
Figure 1-7: A summary of ovarian cancer groups 
A. The groups of ovarian cancer.  
B. The sub-divisions of the epithelial malignancies. 
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The most common sub-type is the serous malignancies (Seidman et al., 2004, Mutch and Prat, 
2014, Prat and Oncology, 2014). The serous group is sub-divided into two. The high grade 
serous (HGS) is the most frequent (70%) ovarian carcinoma (Gilks and Prat, 2009, Prat, 2012, 
Seidman et al., 2004, Mutch and Prat, 2014, Prat and Oncology, 2014) and is considered to 
have originated in the Fallopian tubes (Prat, 2012, Diep et al., 2015, George and Shaw, 2014, 
Perets et al., 2013), and by the time of detection are mostly at an advanced stage (Prat, 2012, 
Kobel et al., 2008) resulting in an unfavourable prognosis. Recently a genetics based study 
(Domcke et al., 2013) comparing genetic features such as DNA copy-number, mutation and 
mRNA expression data, examined high grade serous malignancies and compared them to the 
genetics of cell lines that serve as supposed models for this type of cancer. They discovered that 
most of the cell lines in use as HGS models are actually not so. They also showed that about 
10% of the HGS tumours and cell lines have a BRCA mutation; each mutation (BRCA 1 or 2) 
was identified in 15% of the tumours but only in about 10% of cell lines (Domcke et al., 2013), 
this data is in disagreement with data previously published (Kobel et al., 2008, Gilks and Prat, 
2009). Breast cancer (BRCA) susceptibility genes, responsible for preventing DNA damage, 
are known for their role in breast cancer development. Mutations in either of the BRCA genes 
increase the risk for breast and ovarian cancers (King et al., 2003, Cancer Genome Atlas 
Research, 2011, Sogaard et al., 2006, Antoniou et al., 2003). In OC BRCA mutations can be 
found only in the epithelial cancer, and are serving as marker for HGS tumours (Domcke et al., 
2013, George and Shaw, 2014). However, as mentioned above not all HGS cell lines have 
BRCA mutation (Domcke et al., 2013).                                                              . 
The second sub-type is the low grade serous (LGS) cancers, accounting for <5% of ovarian 
epithelial malignancies (Gilks and Prat, 2009). Their origin is uncertain, and their identification 
is supported by genetics (Gilks and Prat, 2009, Singer et al., 2003, Jayson et al., 2014). 
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The third epithelial tumour sub-type is the endometrioid malignancies which account for 10% 
of the OC cases (Gilks and Prat, 2009). They are similar to endometrial tumours, (Cho and Shih 
Ie, 2009), and at least some are related to the uterine endometrium (Sainz de la Cuesta et al., 
1996, Catasus et al., 2004).                                                                                                                                             . 
The fourth sub-type, clear cell tumours, cells with clear cytoplasm, account for 10% of the 
epithelial malignancy cases (Gilks and Prat, 2009). Their source is controversial but some 
consider it to be of endometrial origin (Diep et al., 2015, Kato et al., 2006, Tan and Kaye, 
2007). Despite the fact that the disease is usually detected at an early stage, the prognosis is not 
favourable (Gilks and Prat, 2009), as they do not respond to commonly used chemotherapy 
(Goff et al., 1996). These cells are not limited to any one of the tumour types and therefore are 
difficult to diagnose (Cho and Shih Ie, 2009, Gilks and Prat, 2009). Nevertheless, there are 
several genetic / molecular markers that might allow for better identification (Kobel et al., 2009, 
Wiegand et al., 2010, Prat, 2012, Kato et al., 2006, Tsuchiya et al., 2003).  
The fifth epithelial sub-type is the mucinous tumours which account for 10-15% of ovarian 
tumours, but only of 3% of ovarian carcinomas (Prat, 2012). They are usually detected in an 
early stage (Jayson et al., 2014), and are mostly non-malignant (Prat, 2012). Many are probably 
metastases from the lower intestinal tract (Diep et al., 2015). 
The second main group of OC is the malignant germ cell tumour. Germ cell tumours as a group 
account for 20-25% of ovarian tumours (Smith et al., 2006, Pectasides et al., 2008), but only 
account for 3-5% (Prat and Oncology, 2014, Tewari et al., 2000) of malignancies, and most 
malignant cases are detected at an early stage (Pectasides et al., 2008). Those malignancies 
mostly occur in children and young women (Tewari et al., 2000, Park et al., 2015, Smith et al., 
2006) and have a good prognosis. The germ cell malignancies are sensitive to chemotherapy 
and have good survival rates (Gershenson, 2012, Pectasides et al., 2008). According to the 
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World Health Organisation, there are five sub-types of germ cell cancers (Rijlaarsdam et al., 
2015), and the three most common are dysgerminoma, yolk sac and immature teratomas 
accounting for more than 90% of malignant cases in this group. 
 
The third and last OC group to be discussed is the sex cord-stromal malignant tumours, the 
rarest group, accounts for 1-2% of cases (Mutch and Prat, 2014). The commonest in the group 
is the granulosa tumour (Prat and Oncology, 2014), and most patients are adults (Kalfa et al., 
2009). The granulosa cells in these tumours have the same gene expression as normal 
proliferating granulosa cells, indicating that they respond to FSH, and that their proliferation is 
related to its stimulation (Fuller et al., 2002). The other members of the family are thecoma-
fibromas, Sertoli cell tumours, sex cord tumours with annular tubules, and gynandroblastomas 
(Kalfa et al., 2009). Most of the data regarding sex cord-stromal tumours has been gathered 
from testicular tumour counterparts. 
 
Cell lines are used as models for cancer, and OC is no different, with cell lines for most if not 
all types of tumours. As the ovaries are steroidogenic tissues it could be expected that the 
steroidogenesis capabilities would have been examined in the cell lines. Unfortunately, such 
data is lacking, and in most cases the data is conflicting. Most of the information comes from 
granulosa cells and epithelial tissue (Zhang et al., 2000, Havelock et al., 2004). Moreover, the 
data collected is not from a systematic study but a result of the general use of the cells or tissues 
during a study. Nevertheless, in cancer related studies it was demonstrated that steroids and 
their receptors have a role in tumour development. Progesterone receptor expression varies 
between the different cancers; 67% of endometrioid tumours, 60% of low grade serous and in 
only 30% of the high grade serous tumours (Diep et al., 2013, Sieh et al., 2013). It would appear 
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that there is a correlation between expression and survival. As mentioned earlier in this section, 
progesterone has an anti-proliferative effect (Yu et al., 2001, Syed et al., 2001, Keith Bechtel 
and Bonavida, 2001, Bu et al., 1997) and progesterone receptor type B (PR-B) indicates a 
favourable prognosis (Diep et al., 2015). The effect of oestrogens is not clear, as some data 
suggest it has an anti-proliferative effect while other data suggest the opposite (Wimalasena et 
al., 1992, Li et al., 2014). Ovarian cancer is also affected by LH and FSH, which support cell 
proliferation (Mertens-Walker et al., 2012, Wimalasena et al., 1992, Choi et al., 2007), and 
decreases apoptosis (Choi et al., 2007). Their effect differs, while FSH increased proliferation 
in 16 of 17 cell lines tested in 20 studies, the LH effect is mixed, with different studies showing 
different results for the LH effect (Lukanova and Kaaks, 2005). It is nevertheless possible to 
say that FSH has a proliferative effect whereas the LH effect needs to be further investigated 
(Lukanova and Kaaks, 2005).  
 
1.4 Summary 
Steroid hormones are important to body function, regulating salt concentrations and glucose 
distribution, most importantly in stress conditions. They are mainly synthesised in the adrenal 
glands, ovaries and testes. 
Three steroid related cancers have been discussed above. The adrenocortical carcinoma (ACC) 
a rare and lethal cancer of the adrenal cortex in the majority of cases affecting steroidogenesis. 
Prostate cancer is a common cancer and is androgen dependent. Late stage treatments are 
designed to inhibit the androgen activity in the tumour and treatments are not curative and the 
tumour continues to grow even when the body is deprived of androgens, utilising the alternative 
pathways to bypass the pharmaceutically induced inhibition. Better treatments are needed. 
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Ovarian cancer is known as the silent killer since in most cases there are no warning symptoms 
and signs until too late. The survival rates depend on the stage of detection but also on the 
cancer type as some are more responsive to treatment than others. The tumours are clearly 
hormone dependent, but no systematic steroid analysis has been performed. Moreover, research 
studies suggest that the OC, in some cases is actually a metastasis from another part of the 
reproductive tract and only the late discovery of it has classified it as OC. The most common 
tumour, serous, originates in the Fallopian tube. Data regarding steroidogenesis or steroid 
effects on tumours and cell lines is scarce, and often contradictory.  
Based on the body of evidence detailed in this chapter, hypotheses about the role and source of 
steroids in two lethal cancers, prostate and ovarian, were raised. Another point that was 
examined was the steroidogenesis of three adrenocortical carcinoma cell lines.  
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2.0 Hypotheses and Aims 
Steroids have a role in cancer development and progression. In this thesis adrenocortical 
carcinoma cell lines served as a model for adrenal steroidogenesis in order to determine if DHT 
alternative biosynthesis pathway androgens have a role in the transformation of prostate cancer 
to castration resistant. In the second section of this thesis ovarian cancer cell lines were used as 
a model to determine if ovarian cancer has the capability to synthesise steroids.   
Characterisation of three adrenocortical carcinoma cell lines derived from the H295 cell 
line.  
The adrenal gland can synthesise three groups of steroids and it is the largest source of steroids 
in the body. In section 4.0, the steroidogenesis capabilities of three distinct cell lines derived 
from the H295 cell line is analysed using mRNA and steroid measurements.  
Alternative androgen synthesis in the adrenal gland may underpin castration resistant 
prostate cancer.                                              . 
Prostate cancer is an androgen dependent cancer, yet in a large percentage of patients the tumour 
progresses even when deprived of androgen and evolves into castration resistant prostate 
cancer. According to previous research, it is possible that the adrenal gland bypasses the 
CYP17A1 inhibition. In chapter 5.0, an adrenocortical carcinoma cell line serves as a model 
and gene knockdown is used to inhibit gene activity in order to mimic the effects of the drug 
abiraterone. Knockdown efficiency is examined using mRNA analysis and steroid 
measurements. 
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We believe that ovarian steroid metabolism can serve as a biomarker to detect ovarian 
cancer.   
Due to the lack of literature about ovarian cancer steroidogenesis, in chapter 6.0, the 
steroidogenesis in four ovarian cell lines is examined using mRNA for enzymatic analysis and 
steroid measurements. In order to eliminate the problems of low level steroidogenesis, steroid 
precursors and forskolin are added to increase steroidogenesis.  
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3.0 General methods and materials 
3.1 Cell Culture 
3.1.1 General Principles  
All cell lines were grown in T75 flasks (CellStar, Greiner, Frickenhausen, Germany) in 10-
15ml of appropriate media. Before the experiments were commenced cells were detached from 
the flasks, using 2ml trypsin (TrypLE Express, Gibco, Life technologies ̶ Thermo Fisher 
Scientific, Paisley, UK). The trypsin activity was then neutralised with 8ml of medium and the 
cells centrifuged at 1200rpm for 5 minutes. The medium was removed and the cells were re-
suspended before counting, using Cells Fastread (Biosigma (ISC), Palgnton, UK) and then 
seeded into 6-well plate (CellStar, Greiner), see relevant chapters for details. The various cells 
were allowed to attach overnight in full culture medium before treatment the next day. 
Treatments were given in phenol-red free media (OAW42: Gibco 11880-028+ L-Glutamine 
PAA M11-044 (The cell culture company, Pasching, Austria), A2780: Gibco 11835-063 and 
COV434/CaOv3: Sigma P1145, H295R1/ H295R-S1 Gibco 21041m H295R-S2/S3 Gibco 
11039-21). The use of phenol-red free medium was at the request of the mass spectrometry 
team due to the fact that the phenol-red blocks the LC-MS/MS column. 
In order to increase steroidogenesis forskolin (FSK) was used. Forskolin connects directly to 
the enzyme adenylate cyclase (cAMP), which regulates many cell events including hormone 
activity and gene regulation, thus causing an increase in enzyme levels and activity creating a 
cascade of reactions ending in an increase in cell steroidogenesis (Williams-Ashman and Reddi, 
1971, Hedin and Rosberg, 1983, Nakamura et al., 2016, Mangelis et al., 2016).  
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3.1.2 Adrenocortical Carcinoma Cell Line 
All the adrenal cells discussed here were derived from the same parent cell line NCI-H295, 
derived from an adrenocortical carcinoma mass removed from the right adrenal of a 48 year old 
woman of black ethnicity from the Bahamas (Gazdar et al., 1990). The tumour cells were grown 
and pure floating cells were chosen to continue cell propagation (Gazdar et al., 1990). Cells 
were also grown in two types of media, HITES and Roswell Park Memorial Institute 1640 
(RPMI1640); in the former, cells were free-floating, and in the latter, adherent. Since the 
original cell line had a long doubling time (>96 h) (Rainey et al., 1994) and were not growing 
in a monolayer, an attempt was made to receive monolayer cells by using a different medium 
resulting in shorter doubling time. After a three month selection period a monolayer growth 
was achieved (Rainey et al., 1994). This cell line was designated as H295R. Later modifications 
in the medium resulted in two other strains (Rainey et al., 2004, Wang and Rainey, 2012). 
H295R1 cell line (H295R, ATCC no.CRL-2128). The H295R1 cells were received from 
Professor Enzo Lali’s laboratory (University of Nice, France). The cells were grown in 
Dulbecco's modified eagle medium/F12 (DMEM/F12) with L-Glutamine medium (Gibco) 
enriched with 2% Nu-Serum (Becton, Dickinson and Company, BD, Oxford, UK), 1% ITS+ 
(insulin, transferrin and selenium, BD) and 1% penicillin-streptomycin (P/S) (PAN BIOTECH, 
Aidenbach, Germany). 
H295R-S1 cell line. The cells were derived from H295 (Wang and Rainey, 2012, Gazdar et al., 
1990, Rainey et al., 1994, ATCC, 2014b) as described in the beginning of section 3.1.2. The 
cells were received from the William E Rainey’s laboratory (University of Michigan, MI, 
USA). They were grown in DMEM/F12 medium with HEPES ((4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)), 15nM (Gibco) enriched with 5% Nu-Serum, Gentamicin 
Reagent Solution (1ug/ml) (Gibco) and 1% P/S. 
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H295R-S2 cell line. The cells were derived from H295 (Wang and Rainey, 2012, Gazdar et al., 
1990, Rainey et al., 1994, ATCC, 2014b) as described in the beginning of section 3.1.2. The 
cells were received from the William E Rainey’s laboratory. They were grown in DMEM/F12 
medium with HEPES, 15nM (Gibco) enriched with 2.5% Ulstroser G (France, St-Germain-en-
Laye, France, #15950-017),1% ITS+, Gentamicin Reagent Solution (1ug/ml) and 1% P/S. 
H295R-S3 cell line. The cells were derived from H295 (Wang and Rainey, 2012, Gazdar et al., 
1990, Rainey et al., 1994, ATCC, 2014b) as described in the beginning of section 3.1.2. The 
cells were received from the William E Rainey’s laboratory. They were grown in DMEM/F12 
medium with HEPES, 15nM enriched with 10% Cosmic Calf Serum (Hyclone, Thermo Fisher 
Scientific), Gentamicin Reagent Solution (1ug/ml) and 1% P/S. 
3.1.3 Ovarian Cancer Cell Lines  
Ovarian cell lines were chosen in order to cover a wide range of ovarian cancer subtypes based 
on use in literature (internal correspondence, not detailed), and secondly according to their 
commercial availability. Out of the variety of cells available, it was decided to use cell lines 
from three common ovarian cancer tumours and a cell line derived from steroidogenic cells.  
A2780 cell line (Public Health England (PHE) no. 93112519). The cell line was derived from 
primary tumour of an untreated patient (Public Health England) and considered to have an 
epithelial morphology (Public Health England). The tumour was classified as an endometrioid 
tumour (Anglesio et al., 2013). Cells were grown in RPMI1640 medium (Gibco) enriched with 
10% foetal bovine serum (FBS) (Sigma-Aldrich (Merck), St. Louis, MO, USA) and 1% P/S. 
COV434 cell line (PHE no. 07071909). A granulosa cell line that was derived from a solid 
primary tumour (Public Health England). No further details could be obtained. The cells were 
grown in DMEM (Dulbecco's Modified Eagle's Medium) high glucose (Sigma-Aldrich) 
enriched with 10% FBS and 1% P/S. 
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CaOv-3 cell line (The American Type Culture collection (ATCC) no. HTB-75). The cell line 
originated from a 54 year old female with an ovarian adenocarcinoma (ATCC, 2014a). The 
cells were grown in DMEM high glucose enriched with 10% FBS and 1% P/S. 
OAW42 cell line (PHE no. 85073102). The cell line was derived from a 46 year old patient 
with ascites due to an ovarian cystadenocarcinoma (Wilson, 1984), described as being of 
papillary serous type. The cells were grown in DMEM (Gibco) enriched with 10% FBS and 1% 
P/S. 
3.2 Messenger RNA Expression Analysis  
3.2.1 RNA Isolation 
At the end of the experimental period, usually 72h after treatment, the medium was removed 
and 1ml of Tri Reagent (Sigma-Aldrich) was added to the wells and the cells were collected 
into 1.5ml microfuge tubes and stored at -20ºC for future analysis. For RNA isolation, 200µl 
chloroform (all volumes are according to the use of 1ml Tri Reagent for cell collection) was 
added to the Tri Reagent. Samples were briefly vortexed and then incubated at room 
temperature for 10 minutes before centrifugation at 16,000xg for 10 minutes. Subsequently, the 
upper layer was transferred to a new tube and 0.5ml of isopropanol was added and vortexed 
prior to being incubated for 40-60 minutes at -20ºC for enhanced RNA yield. After 
precipitation, the samples were centrifuged for 10 min at 16,000xg. The supernatant was 
removed leaving behind a small pellet. One millilitre of 70% ethanol was added, as a washing 
step, and it was then vortexed before being centrifuged for 5 minutes at 16,000xg. The 
supernatant was removed and samples were left to dry for up to 15 minutes. Thereafter 20-25µl 
of nuclease free water (Promega, Madison, WI, USA) was added. The RNA concentration and 
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quality were measured with Nano-Drop ND-1000 photospectrometer (Labtech International, 
Uckfield, UK).  
The RNA of the H295R-S1 cells was extracted by a colleague, Dr Vasileios Chortis from the 
Institute of Metabolism and Systems Research at the University of Birmingham, using Qiagen 
RNeasy mini kit (Hilden, Germany), according to the manufacturer’s protocol.  
3.2.2 Reverse Transcriptase  
RNA (1000ng) was added into a reverse transcriptase (RT) reaction mix. Each reaction sample 
contained 2µl of 10X RT buffer, 4.4µl of 25mM MgCl2, 4µl 10mM dNTPs (DNA nucleotides), 
0.5µl 2.5µM oligo (dT), 0.5µl 2.5µM random hexamers, 0.4µl RNAse inhibitor and 0.5µl of 
50u/µl multiscribe RT enzyme (TaqMan kit, Applied Biosystems – Thermo Fisher Scientific, 
Paisley, UK). A total of 20µl, containing 13µl of the above of the reaction mix, 7µl RNA and 
RNAse free water were loaded into a polymerase chain reaction (PCR) plate (Thermo Fisher 
Scientific) and amplified using a GeneAmp PCR system 2700 (Applied Biosystems – Thermo 
Fisher Scientific). The RT reaction was performed under the following cycle conditions:  25ºC 
for 10 minutes, 37ºC for 60 minutes, 48ºC for 30 minutes and 95ºC for 5 minutes. At the end 
of the reaction, 105µl of RNAse free water was added for a final concentration of 8ng/µl cDNA.  
3.2.3 Real Time Quantitative PCR (qPCR) 
The real time polymerase chain reaction (PCR) system is based on fluorescent light 
measurement to determine the amount of complementary DNA (cDNA) of a specific gene. The 
TaqMan real-time PCR technology is based on a pair of unlabelled primers and a labelled 
oligonucleotide probe. The probe has two dyes; a 5’ receptor and 3’ quencher, the quencher dye 
reducing the receptor fluorescent illumination. During the reaction, the primers and probe are 
annealed to their specific location on the cDNA template, and a Taq-polymerase synthesises a 
new strand based on the primers and template. During this stage, the 5’ dye is removed from 
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the probe and without the restriction of the 3’ quencher dye its signal increases. At the end of 
each cycle a measurement of the fluorescent illumination is performed. The more cycles passed 
the higher the signal (Figure 3-1). With this method, it is possible to find the first time a target 
is detectable, but not the target levels. The first cycle in which the target is detected is referred 
to as the threshold cycle (Ct) value, and the higher the number of target copies in the original 
sample the lower the Ct at which its fluorescent illumination is first detected. By comparing the 
target gene to housekeeping genes, a relative quantification of the different target genes is 
possible. 
Each quantitative PCR (qPCR) sample contained 5µl TaqMan 2X PCR master mix (Applied 
Biosystems), 3µl primers and probe mix and 16ng cDNA in 2µl per sample, or 2µl RNAse free 
water as control, totalling 10µl. Primer and probe mixes (TaqMan-on-demand) were ordered 
from Life Technologies or Sigma (see relevant chapters for genes names and catalogue 
numbers). The qPCR samples were loaded into a 384 well plate (Applied Biosystems) and ran 
in a 7900HT qPCR machine (Applied Biosystems) using the following programme: 50ºC for 2 
minutes followed by 40 cycles of 95ºC for 15 seconds and then 60ºC for 1 minute. Their Ct 
value was used for the analysis. Ct (gene of interest Ct minus housekeeping gene Ct) and fold 
change (2^(Ct)) were calculated. These were used for statistical analysis. Ct values above 40 
were considered as “no expression” and marked 40 for analysis purposes. 
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3.3 Protein Measurements 
Proteins were collected for steroid analysis normalization. They were isolated from cells 
collected in radioimmunoprecipitation assay (RIPA) buffer (50mM Tris hydrochloric acid 
(HCl) pH 8 (Sigma-Aldrich), 150 mM sodium chloride (NaCl, Sigma-Aldrich), 0.5% sodium 
deoxycholate (Sigma-Aldrich), 1% IGEPAL (octylphenoxypolyethoxyethanol) Ca-630 
(Sigma-Aldrich), 1 mM ethylenediamine tetra-acetic acid, disodium salt dehydrate MW272.2, 
Sigma-Aldrich) and 0.1% sodium dodecyl sulfate (SDS, Fluka- Sigma-Aldrich) and protease 
inhibitors cocktail (PIC, Roche, Burgess Hill, UK). Proteins from H295R1 cells were isolated 
using ready-made RIPA buffer (Sigma). Samples were frozen in dry ice and then thawed at 
37ºC in two cycles before being centrifuged for 10 minutes at 16,000xg. The supernatant was 
collected and transferred to a 1.5 or 0.2 microfuge tube and stored at -20ºC.  
The Bradford assay was used to measure protein concentrations. Coomassie Brilliant Blue G-
250 dye binds to the basic amino acids, arginine, lysine and histidine present in the protein. The 
binding causes the dye to change colour from red to blue. The measurements were done in 
triplicate with a Bradford kit (Bio-Rad, Hertfordshire, UK), according to manufacturer’s 
Figure 3-1: Schematic of quantitive PCR method 
A. The probe with the receptor (pink) and quencher (black) are attached to the 5’-3’ cDNA template and the polymerase  
     synthesises the complementary strand.  
B. The polymerase cleaves the probe during DNA synthesis.  
C. Once the receptor is detached from the quencher, it starts emitting light. 
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instructions. Briefly, 5µl of sample and 225µl of Bradford mix were added to a 96 well plate. 
After five minutes incubation at room temperature on a plate shaker (~1000rpm), samples were 
measured at 690nm on a PerkinElmer VICTOR3 multilabel counter (Waltham, MA, USA) and 
analysed in comparison to a standard curve of bovine serum albumin (Sigma). 
3.4 Short Interfering RNA (siRNA) Knockdown  
H295R1 cells were seeded into a 6-well plate, 5x105 cells/well and left to attach overnight 
before transfection by Viromer® (Lipocalyx GmbH, Halle (Saale), Germany). Viromer® is a 
high-tech polymer that mimics the influenza virus membrane fusion mechanism to insert short 
interfering RNA (siRNA) into cells. The polymer has fatty acids and alkyl areas mimicking two 
amino acids on the influenza virus that are needed for virus cell invasion, namely Glutamine 
and Alanine (respectively). The siRNA is attached to the polymer prior to the transfection (see 
below). The particles enter the cell in endosomes, and the pH change (from pH 7 to pH 5) causes 
them to release the siRNA enabling them to attach to the mRNA (Figure 3-2). A comparison of 
transfection efficiency was initially undertaken between the two Viromer products designed for 
siRNA transfection, Viromer BLUE or GREEN. Viromer BLUE was chosen. The transfection 
mix was prepared according to the manufacturer’s recommendation to the highest transfection 
levels (11µM siRNA and 5.5µl Viromer in Buffer F) and incubated at room temperature for 10 
minutes. The cell media was replaced with 1ml growth medium, and the 150µl (1.5:10 ratio to 
media) Viromer™ mix was added to the medium in each well. Cells were incubated for 48 
hours. Then the medium was replaced with 1ml phenol-red free experiment medium with 1µM 
FSK (Sigma-Aldrich) in dimethyl sulfoxide (DMSO, Sigma-Aldrich) for another 24 hours 
before terminating the experiment. The medium was then collected for steroid analysis and cells 
were collected in Tri Reagent or RIPA buffer for RNA isolation and protein measurement 
respectively. 
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 Viromer – siRNA complex 
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3.5 Steroid Conversion Assays  
Ovarian cells were seeded 5x105-1.25x105 cells/well in media, and left overnight to attach at 
37°C with 5% CO2. Thereafter, the medium was removed and replaced with the relevant 
phenol-red free medium, containing the relevant steroid substrate (pregnenolone, 17OHP or 
androstenedione), at concentrations of 200nM, 500nM or 1000nM. The cells were then 
incubated for 72h before the medium and cells were collected for steroid analysis and protein 
measurement. 
3.6 Steroid Extraction and LC-MS/MS 
A Xevo liquid chromatography-tandem mass spectrometer (LC-MS/MS) with Acquity uPLC 
system (Waters, Elstree, UK) was used to measure steroid concentrations in the cell media. The 
conditions for the LC-MS/MS electrospray ionization source were 4kV capillary, source 
temperature 150ºC and desolvation temperature of 500ºC (Figure 3-3). The LC-MS/MS allows 
for accurate measurement of the steroids based on their mass/charge ratio. The steroids 
extracted into a liquid phase, are loaded onto a column containing a solid stationary phase. The 
steroids bind to the solid phase, and by changing of the liquid phase polarity, the steroids elute 
into the mass spectrometer. The steroid identity is determined based on the retention time (the 
H
+
 
Figure 3-2: The Viromer siRNA insertion mechanism 
The siRNAs are attached to the polymer using a special buffer and then the complex is added to the cell medium.  
The polymer-siRNA complex is inserted into the cell by endocytosis and an endosome is formed. The pH change in the 
endosome causes the detachment of the siRNA from the polymer allowing the siRNA to enter the cell and to attach to an 
mRNA strand. This figure is based on the Viromer instruction sheet. 
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time it took the steroid to travel through the column), steroid mass/charge ratio (m/z) and the 
ions created when fragmented. For steroid extraction, 20µl of an internal standard solution 
containing deuterated steroids (Steraloids, Newport, RI, USA or Sigma-Aldrich, St. Louis, MO, 
USA) in LC-MS/MS grade methanol (Greyhound Chromatography, Merseyside, UK) was 
added to 1ml of cell medium that was used for the incubation and was then vortexed. Three 
millilitre MTBE (tert-butylmethyl ether, Sigma-Aldrich, St. Louis, MO, USA) was added, and 
samples were vortexed and stored for at least an hour and up to 24h at -20ºC. The upper phase 
containing the steroids was transferred into a 96 well LC-MS/MS plate (Thermo Fisher 
Scientific, Paisley, UK or Porvair Sciences Limited, Wrexham, UK), and was evaporated at 
60ºC under nitrogen. Once all the MTBE was collected and evaporated, 125µl of 1:1 methanol 
/water (Fisher) (LC-MS/MS grade) was added to each well and the plate was stored at -20ºC 
for LC-MS/MS measurement and analysis. Concentrations were quantified relative to a linear 
standard curve containing the steroids of interest in known concentrations ranging from 0.5 to 
500 mg/ml. 
Figure 3-3: LC-MS/MS schematic 
A mixture of steroids is injected into the machine. Each steroid is fragmented to two ions that can be detected and identified. 
According to the retention time (time to reach the mass spectrometer), mass and ions relative to authentic steroid standards 
the identity of the different steroids can be determined. Adapted from internal department datasheets by Dr A. Taylor. 
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3.7 Statistical Analysis  
Statistical analysis was performed using Prism 6 (GraphPad, La Jolla, CA, USA). QPCR results 
were transformed using Y=Log(Y) and LC-MS/MS results were analysed directly. Analysis 
was performed using the non-parametric unpaired two-tailed t-test for single variant analysis 
(Mann-Whitney test) or one-way non-parametric ANOVA with multiple comparisons corrected 
by the Bonferroni test for multi-variant results.  
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4.0 Steroidogenesis in Adrenocortical Carcinoma (ACC) Cell Lines 
4.1  Introduction 
The adrenocortical cell line (H295) has the capability to synthesise all adrenal steroids (Gazdar 
et al., 1990). NCI-H295R (H295R) and the three strains H295R-S1, -S2 and -S3 were derived 
from the same parent cell line (Rainey et al., 2004, Rainey et al., 1994, Wang and Rainey, 
2012), created under different growing conditions (see Method section 3.1.2).                                                                                            
Adrenal steroidogenesis is a compartmentalised process, each of the three cortical zones are 
responsible for different types of steroid, as describe before (Section 1.1). Briefly, the zona 
glomerulosa synthesises mineralocorticoids, zona fasciculata synthesises glucocorticoids and 
zona reticularis synthesises androgen precursors. In a clinical trial by Attard and colleagues 
(Attard et al., 2012), alternative pathway steroid metabolites were measured in castrated 
patients with elevated androgens prior to abiraterone treatment. In order to examine the 
possibility that adrenal cells contribute to prostate cancer growth by the alternative pathway, 
their steroidogenesis first needed to be characterised. The above adrenal cell lines, chosen as an 
in vitro model of adrenal steroidogenesis were examined using qPCR and LC-MS/MS analysis 
in order to characterise their steroidogenesis capability.  
4.2 Methods 
4.2.1 Cell Culture 
Cells were seeded in 6-well plates, 5x105 cells/well, in the appropriate medium, and allowed 
to attach overnight at 37°C with 5% CO2. Their density was based on confluence experiments. 
The cells were seeded at different concentrations for 96 hours to determine the cell 
concentration that will give the best confluence for the duration of an experiment, and was the 
same for all H295R cell lines. Thereafter, the medium was removed and replaced with the 
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equivalent phenol-red medium, with or without 1µM forskolin (FSK). The cells were incubated 
at 37°C with 5% CO2 for 72 hours, based on a time course experiment designed to determine 
the best time point for steroid measurements. Media, for steroid analysis, and cells, for mRNA 
analysis and protein, were collected as described before (section 3.0), at the end of each 
experiment.  
4.2.2 Steroidogenesis Characterization  
The adrenal cell lines H295R-S1, S2 and S3 were grown in flasks in their respective medium, 
as described in section 3.0, to a 75-90% confluence, and then detached as described in section 
3.1, and seeded in 6-well plates. After an overnight attachment period, the medium was replaced 
with a phenol-red free including the relevant supplements as described previously (section 3.0) 
and 1µM FSK was added to the experiment wells while the control wells had media with no 
added FSK. Later, the experiment was repeated using media with charcoal stripped serum, 
serum treated with charcoal to reduce steroid concentrations in serum, to examine if the steroids 
in the serum or in the serum supplements affected steroidogenesis.  
4.2.3 QPCR (Quantitative Polymerase Chain Reaction) 
Quantitative polymerase chain reaction (qPCR) was performed as mentioned in the general 
methods (section 3.2.3) using two housekeeping genes and steroidogenesis related target genes, 
see Table 1 for details.  
Table 1: The genes used for qPCR analysis of H295R-S1, -S2 and -S3 steroidogenesis characterizations  
Gene name Enzyme Catalogue 
number 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase (housekeeping) 
Custom  
 order 
PROBE [6FAM]CGCCCAATACGACCAAATCCGTTGAC[TAM] 
FOWARD ATGGGGAAGGTGAAGGTCG 
REVERSE TAAAAGCAGCCCTGGTGACC 
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Table 1 (cont.): The genes used for qPCR analysis of H295R-S1, -S2 and -S3 steroidogenesis characterizations 
Gene name Enzyme Catalogue 
number 
HPRT1 Hypoxanthine phosphoribosyl transferase 1 (housekeeping) 
Custom  
 order 
PROBE [6FAM]CAAGCTTGCGACCTTGACCATCTTTGGA[TAM] 
FOWARD TGCTTTCCTTGGTCAGGCAGTAT 
REVERSE TCAAATCCAACAAAGTCTGGCTTATATC 
CYP11A1 Cytochrome P450 family 11 subfamily A member 1  Hs00167986 
HSD3β1 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 1 
Hs04194787 
HSD3β2 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 2 
Hs00605123 
CYP17A1 Cytochrome P450 family 17 subfamily A member 1 Hs01124136 
CYP21A2 Cytochrome P450 family 21 subfamily A member 2 Hs00416901 
CYP11B1 Cytochrome P450 family 11 subfamily B member 1 Hs01596404 
CYP11B2 Cytochrome P450 family 11 subfamily B member 2 Hs00167984 
POR P450 (cytochrome) oxidoreductase (electron transferase) Hs00287016 
17βHSD1 Hydroxysteroid (17-beta) dehydrogenase 1 Hs00166219 
17βHSD3 Hydroxysteroid (17-beta) dehydrogenase 3 Hs00970002 
17βHSD10 Hydroxysteroid (17-beta) dehydrogenase 10 Hs00189576 
AKR1C1 Aldo-keto reductase family 1, member C1  Hs00413886 
AKR1C3 Aldo-keto reductase family 1, member C3 Hs00366267 
RDH5 Retinol dehydrogenase 5 Hs00161263 
RDH16 Retinol dehydrogenase 16 Hs00559712 
SRD5A1 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 1) 
Hs00602694 
SRD5A2 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 2) 
Hs001658543 
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4.3 Results 
4.3.1 Steroidogenic Profile 
H295R cell lines were derived from one parent cell line (Wang and Rainey, 2012, Gazdar et 
al., 1990, Rainey et al., 1994), and thus their steroidogenic gene expression was similar to each 
other. The results presented here will show that although having similar steroidogenic gene 
expression, the steroid production varied between the cell lines. Gene analysis of 16 
steroidogenic enzymes (Figure 4-1) showed that the three cell lines characterised (H295R-S1, 
-S2 and S3) expressed the examined steroidogenic genes demonstrating that the cells had the 
potential to synthesise mineralocorticoids, glucocorticoids and sex hormones (expression level 
in H295R-S1 20-40 Ct, H295R-S2 22-37 Ct and for H295R-S3 20-39 Ct). The steroidogenic 
gene expression profile is very similar between the cell lines. All the cell lines expressed 
CYP11A1, CYP21A2, CYP17A1, SRD5A2, HSD17B10 and AKR1C3 at high levels, and the 
other genes expression pattern is similar. The variations in expression levels affect steroid 
production, since mRNA is translated to proteins, higher levels of mRNA may indicate 
higher levels of enzymes which could affect the steroidogenic metabolism (Figure 4-1 and 
Figure 4-3). In H295R-S1 (Figure 4-1 A) the CYP11B levels were relatively low compared to 
the other cell lines, suggesting that this cell line was less able to synthesise gluco- and mineralo-
corticoids, which was supported by steroid analysis. However, the low n number (N=1), 
prevents this data from being conclusive. Treatment with 1µM FSK did not cause any 
significant affect in H295R-S1 cells, although both H295R-S2 and S3 were significantly 
affected in gene expression (Figure 4-2 A and B) and steroid levels (Figure 4-3 B and C). 
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4.3.1.1 H295R-S1 
The H295R-S1 (S1) cell line was derived from the parent cell line by serum supplement 
modification as describe by Rainey et al. (Rainey et al., 2004, Wang and Rainey, 2012). In 
brief, the cells were grown in a medium containing a serum replacement, Nu-Serum. After 48h 
incubation, with or without FSK, 10 steroids were detected in the medium (Figure 4-3 A), but 
only androstenedione showed significant difference between the controls (left bar) and the FSK 
treatment (right bar). The combination of the steroid and gene analysis indicates that these cells 
synthesise mostly androgens, though less testosterone than other androgens. The results suggest 
that their mineralo- and glucocorticoid synthesis were also limited due to low CYP11B enzymes 
levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Steroidogenesis gene profile in H295R-S1, H295R-S2 and H295R-S3 cell lines 
The baseline gene expressions of H295R-S1 (A), -S2 (B) and –S3 (C) cell lines demonstrate that the cells have the potential 
to synthesise all of the steroid groups synthesised by the adrenal cortex. The results indicate that the cells express the same 
genes but at different levels. H295R-S1 has the lowest expression of CYP11B genes, however low n numbers prevent data 
from being conclusive. The expression levels of the genes in H295R-S2 and S3 are similar. Suggesting that the cells are able 
to synthesise androgens more easily than gluco- or mineralocorticoids. H295R-S1 experiments were performed in serum-free 
media 48h, N=2, except CYP11B2 N=1. H295R-S2 and H295R-S3 experiments were performed in full media, incubation 
time is 72h. N=3. Results shown as Mean±SEM.  
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Figure 4-2: Forskolin effects on steroidogenic enzymes in H295R-S2 and -S3 cells 
H295R-S2 (A) and H295R-S3 (B) were exposed to 1µM FSK for 72h and mRNA levels were analysed. Of 16 genes 
analysed, only seven (S2) or three (S3) genes were significantly affected by the FSK. Expression of all the genes, except 
AKR1C3, was increased under the FSK treatment.  
The cells were treated with 1µM FSK for 72h. Significance relative to the control level *=P<0.05, **=P<0.01 
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Figure 4-3: Steroidogenesis in H295R-S1, -S2 and -S3 cell lines 
H295R-S1 (A), H295R-S2 (B) and H295R-S3 (C) were derived from the same parent cell, nevertheless, their steroidogenesis 
profiles differ. H295R-S2 and -S3 synthesise the same steroids, while H295R-S1 does not synthesise measurable levels of 
progesterone, 17-OH-pregnenolone and androstanedione. The steroid concentrations vary between the cell lines, but all cell 
lines present the ability to synthesise all the adrenal steroids. DOC – deoxycorticosterone, 17OHP – 17-hydroxyprogesterone, 
17OHpreg – 17-hydroxypregnenolone, DHEA– dehydroepiandrosterone. 
Left bar: control; Right bar: 1µM FSK. H295R-S1 – 48h, H295R-S2 and S3 – 72h Mean±SEM 
N.D – non detected*=P<0.05, **=P<0.01, ***=P<0.005. H295R-S1 48h incubation, N=3 H295R-S2 72h N=3, H295R-S3 
72h, N=3  
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4.3.1.2 H295R-S2 
The H295R-S2 (S2) cell line was derived from the parent cell line by serum supplement 
modification as describe by Rainey et al. (Rainey et al., 2004, Wang and Rainey, 2012). Briefly, 
the cells were grown in Ultroser-G supplement, which is known to preserve steroidogenesis and 
used to increase cell growth (Rainey et al., 2004). The levels of expression of steroidogenic 
genes varied between 22-37Ct values (Figure 4-1B) and FSK caused a decrease of 1-2 Ct values 
in responding genes, indicating that FSK caused an increase in gene expression. Of the 16 genes 
analysed only seven were affected significantly by the FSK treatment, six of them increased, 
and one, AKR1C3, was significantly decreased by the treatment (Figure 4-2 A). The effect of 
the FSK is supported in the literature, except for AKR1C3 and RDH16 for which no article 
involving FSK treatment could be found (Schwartz and Roy, 2000, Xing et al., 2010, Kayani 
et al., 2009). Steroidogenic analysis (Figure 4-3 B) identified 13 steroids out of the 30 detected 
in the parent cell line (Rainey et al., 1994). Steroids belong to the three groups of adrenal 
(mineralocorticoids, glucocorticoids and androgen precursors) were detected and their 
concentrations range between 0.2-66 ng/mg protein, yet the levels of progesterone and 
testosterone were very low. It is noteworthy that three of the steroids; deoxycorticosterone 
(DOC), 11-deoxycortisol and androstanedione (Figure 4-3 B) were decreased with FSK (right 
bar) compared to the control (left bar). This, however, did not correlate with the increase in 
gene expression. When the cells were treated with stripped serum to determine as to whether 
the Nu-serum supplement affected steroidogenesis, the gene expression was found to be similar 
to that expressed in full medium, indicating that the medium did not affect the gene levels (Data 
not shown). In another experiment, performed as a pilot, after 72h incubation three steroids of 
the alternative androgen synthesis pathway, 3α5α17HP (3α,5α,17-hydroxypregnenolone), 
androsterone and androstanediol (concentrations at 72h 0.2ng/mg protein 0.17ng/mg protein 
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and 0.72ng/mg protein respectively) were detected (Figure 4-4 A). The alternative pathway 
steroid 5α-pregnan-17-ol-3,20-dione (10µg/L) was previously detected by Kamrath et al. in 
controls of a congenital adrenal hyperplasia study (Kamrath et al., 2012), but no other studies 
supporting this could be found. 
 
 
 
 
 
 
 
 
Figure 4-4: Steroidogenesis in H295R-S2 and H295R-S3 
H295R-S2 (A) and-S3 (B) cells were grown for 72h in appropriate media, and steroidogenesis was measured. Seventeen 
steroids were detected, three of them are alternative pathway steroids. This pathway bypasses the regular DHT through 
testosterone synthesis, resulting in DHT synthesis without testosterone as a precursor. The alternative pathway is known to be 
active in pathologic conditions, as in P450 oxidoreductase deficiency and in castration resistant prostate cancer patients 
treated with abiraterone. In the graph the three alternative steroids together with 17OHP, their precursor can be seen. 
DOC   ̶deoxycorticosterone, 17OHP  ̶ 17-hydroxyprogesterone, 3a5a17HP  ̶ 3α,5α,17-hydroxypregnenolone. N=1 
 
4.3.1.3 H295R-S3 
The H295R-S3 (S3) cell line was derived from the parent cell line by serum supplement 
modification as describe by Rainey et al. (Rainey et al., 2004, Wang and Rainey, 2012). In 
brief, cells were grown in cosmic calf serum. Gene expression (Figure 4-1 C) indicated that the 
cells express all 16 genes examined, and that the cells had the ability to synthesise all of the 
adrenal steroids, glucocorticoids, mineralocorticoids and androgen precursors. However, only 
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three of the 16 genes examined (Figure 4-2 B) were affected significantly by FSK (right bar) 
compare to the control (left bar), and as mentioned in section 4.3.1.2, H295R-S2, these results 
are supported in the literature (Kayani et al., 2009, Xing et al., 2010). In LC-MS/MS steroid 
analysis 13 steroids were measured (Figure 4-3C), the same as in the H295R-S2. However, the 
steroid concentrations, 0.2-147 ng/mg protein, significantly differed between the cell lines 
(Data not shown). Stripped serum was used to examine if the cosmic calf serum steroid 
concentrations affected the results. No differences were detected between the full and stripped 
sera medium (Data not shown). In another experiment, done as a pilot, after 72h incubation 
three alternative androgen synthesis pathway steroids, 3α5α17HP, androsterone and 
androstanediol (concentrations at 72h 3.9ng/mg protein 1.2ng/mg protein and 0.99ng/mg 
protein respectively) were measurable (Figure 4-4 B). As explained in section 4.3.1.2 the 
alternative pathway steroid 5α-pregnan-17-ol-3,20-dione was measured in healthy controls 
(Kamrath et al., 2012).   
4.4 Summary 
H295R cell lines are the only human adrenal cancer cell lines, with steroidogenesis capabilities, 
widely used. Their ability to synthesise all of the adrenal steroids, mineralocorticoids, 
glucocorticoids and androgen precursors, makes them a useful tool in adrenal and 
steroidogenesis research. The H295R strains S1, S2 and S3 were derived from the same parent 
cell line using different serum replacements which created three cell lines that present similar 
steroidogenic gene expressions, but differ in their steroidogenesis, secreting the same steroids 
but at different concentrations. The decreased secretion of DOC, 11-deoxycortisol and 
androstenedione seen in H295R-S2 cells treated by FSK, did not correlate with the gene 
expression levels. Yet, it might be explained as a shift between substrate and metabolite, while 
DOC and 11-deoxycortisol significantly decreased, their metabolites corticosterone and  
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11-dexoycortisol, respectively, significantly increased. A similar thing happens with 
androstenedione and its precursor DHEA, while the former decreased, the latter increased, 
suggesting that the FSK affected the metabolism rate unequally.   
The fact that the S2 and S3 cell lines can synthesise alternative pathway steroids needs to be 
further investigated since this may indicate that these cell lines could serve as a good model for 
conditions involving inhibition of the “classic” adrenal pathways. The results also indicate that 
the H295R cells can serve as a good cell line model for the adrenal cortex. Since cell 
steroidogenesis is sensitive to their growth medium make-up, the growth medium in 
steroidogenic experiments is of great importance. The characterization was a side project during 
a larger project to investigate the possibility that the adrenal gland has a role in prostate cancer 
resistance to castration using adrenocortical carcinoma cell lines as an in vitro model. H295R-
S1, -S2 and -S3 were never characterised before, and this is the first time a full steroidogenesis 
characterisation was performed on them. To-date no normal range of alternative pathway 
steroids is available in either healthy individuals or in diseased. This study was not designed to 
determine if the alternative pathway should be targeted as therapeutic target but only to 
investigate if it has a role in CRPC development. The adrenal cancer cells were used only as a 
model, the role of steroids in adrenocortical cancer was not examined here.       
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Figure 4-5: Steroidogenesis in H295R-S2 and H295R-S3 
H295R-S2 (A) and-S3 (B) cells were grown for 72h in appropriate media, and steroidogenesis was measured. Seventeen 
steroids were detected, three of them are alternative pathway steroids. This pathway bypasses the regular DHT through 
testosterone synthesis, resulting in DHT synthesis without testosterone as a precursor. The alternative pathway is known to be 
active in pathologic conditions, as in P450 oxidoreductase deficiency and in castration resistant prostate cancer patients 
treated with abiraterone. In the graph the three alternative steroids together with 17OHP, their precursor can be seen. 
DOC   ̶deoxycorticosterone, 17OHP  ̶ 17-hydroxyprogesterone, 3a5a17HP  ̶ 3α,5α,17-hydroxypregnenolone. N=1 
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5.0 SiRNA manipulation to reveal cell alternative pathway activity 
5.1 Introduction 
The adrenal gland is a major steroidogenesis organ responsible for the synthesis of 
glucocorticoids, mineralocorticoids and androgen precursors. In 2012, Attard and colleagues 
(Attard et al., 2012) showed that the adrenal glands might have a role in the resistance of 
prostate cancer to abiraterone treatment. Patients treated with abiraterone have a progress free 
period (de Bono et al., 2011, Fizazi et al., 2012, Ryan et al., 2013) but after several months the 
disease continues to progress. Since prostate cancer is androgen dependent (Attard et al., 2008), 
this progress indicates that the abiraterone inhibition is no longer affective and androgens are 
synthesised. The alternative DHT biosynthesis pathway products, serves as better substrates for 
CYP17A1, and 17-OH-allopregnanolone is the most efficient 17,20-lyase substrate (Gupta et 
al., 2003). Therefore, this pathway allows for DHT synthesis even when CYP17A1 is in limited 
availability due to the inhibition. In this project, the possibility that CYP17A1 knockdown in 
the adrenal will result in a shift towards the alternative pathway resulting in androgen or 
androgen precursor synthesis was examined. In order to knockdown the genes CYP17A1, 
CYP21A2 and POR (P450 oxidoreductase) commercial siRNAs were used, and transfection 
was performed using a relatively new method known as Viromer, a high-tech polymer that 
mimics the influenza virus.  
5.2 Methods 
5.2.1 Transfection  
A Viromer-siRNA mix, for transfection of very resistant cells, was prepared according to 
manufacturer’s instructions. Briefly, 18µl of 11µM siRNA (See Table 2 for details) in Buffer 
F were mixed with 5.5µl Viromer in 495µl buffer F. This mix was chosen following an 
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experiment preformed to determine the best combination of Viromer and siRNAs and the time 
point resulting in the best transfection rates.  
Table 2: Silence interfering RNA used for gene knockdown 
Gene name SiRNA Catalogue number  Company 
 Scramble 4390844 Ambion 
(TermoFisher) 
CYP17A1 SiRNA-I HSS102587 Invitrogen 
SiRAN-II HSS102588 Invitrogen 
CYP21A2 SiRNA-I HSS141782 Invitrogen 
SiRAN-II HSS141783 Invitrogen 
POR SiRNA-I HSS108264 Invitrogen 
SiRAN-II HSS182524 Invitrogen 
 
5.2.2 Quantitative PCR 
Following the knockdown, its effect on the mRNA levels of the relevant gene was examined 
according to the methods in section 3.2.3. GAPDH and HPRT1 served as housekeeping genes 
and CYP17A1, CYP21A2 and POR as target genes (for details Table 1). 
5.3 Results 
5.3.1 Viromer Gene Knockdown 
The knockdown experiments were performed as part of a study investigating the possibility 
that the adrenal glands are the source of androgen precursors for prostate cancer when patients 
are treated with the CYP17A1 inhibitor abiraterone. The assumption that an alternative 
androgen synthesis pathway, known from other conditions, is utilised, was examined. In order 
to investigate the possibility that the adrenal bypasses the CYP17A1 inhibition induced by 
abiraterone, H295R1 cells were treated with siRNAs. Based on data from previous research 
 67 
 
(Attard et al., 2012, Arlt et al., 2004), three types of siRNAs were used; namely, anti-CYP17A1, 
anti-CYP21A2 and anti-POR. Gene expression analysis demonstrated that the siRNAs were 
very effective, with 80-98% knockdown of the relevant gene (Figure 5-1). The effect on the 
mRNA was further evaluated with steroid analysis. 
 
 
 
 
   
5.3.2 CYP17A1 Knockdown 
CYP17A1 knockdown was achieved using two siRNAs, resulting in a significant (P<0.001) 
and more than 90% knockdown (Figure 5-1 left, si-I 97.5% and si-II 94%). This represented 
almost total knockdown of the enzyme, similar to the effect of abiraterone treatment in patients. 
However, in-vitro abiraterone did not cause a shift towards the alternative pathway (data not 
shown), although affecting at least three genes at once (Ferraldeschi et al., 2013, Attard et al., 
2012, Huang et al., 2016, Udhane et al., 2016, Li et al., 2012). The siRNAs were used in an 
attempt to cause a shift towards the alternative pathway and possibly determine if the inhibition 
of CYP17A1 is sufficient to cause the shift seen in patients or if it is a combination of two or 
more of the enzymes blocked by abiraterone. Thereafter, the effect on the steroidogenesis was 
examined, and the results were as hypothesised (Figure 5-3). All of CYP17A1 precursors were 
elevated, 5-10 fold higher than control. The products of the 17α-hydroxylase were reduced by 
30-40% compared to scramble (control), depending on the siRNA used. Androgen synthesis 
Figure 5-1: Gene knockdown using siRNA 
H295R1 cells were treated with siRNA against CYP17A1 (A), CYP21A2 (B) and POR (C), for 48h, and then another 24h 
without siRNA but with 1µM FSK, to increase protein yield. All siRNAs resulted in significant knockdown, mainly more 
than 80%, indicating almost complete knockdown of the relevant gene. Results shown as Mean±SEM. **=P<0.01, 
***<P<0.005 relative to scramble. Si-I – siRNA-I and si-II – siRNA-II. N=3 
 68 
 
was reduced by 90% or more to almost undetectable levels. Yet this almost complete 
knockdown, of more than 90%, indicating that almost no mRNA copies of the gene were 
available for transcription, did not result in a detectable shift to the alternative pathway, as 
occurs in castration resistant prostate cancer. The inhibition of the pathway resulted in a shift 
to the glucocorticoid and mineralocorticoid pathways mediated by CYP21A2. 
Deoxycorticosterone (DOC) was elevated 5-8 fold above control and corticosterone was 5-9 
fold higher than in control. Nonetheless, cortisol, a glucocorticoid, which is synthesised through 
17-OH-hydroxylase action, was decreased. Those results are similar to the effect measured in 
patients with congenital inhibition of CYP17A1(Auchus, 2016, Carvalho et al., 2016, Han et 
al., 2016) or in abiraterone treated patients (Attard et al., 2012). 
 
 
 
 
 
 
 
 
Figure 5-2: 
Steroidogenesis in CYP17A1 
knockdown cells 
H295R cells were tranfected with siRNAs against CYP17A1 for 48h and then replaced with a medium containing 1µM FSk 
for another 24h. As anticiepated androgen concentrations were reduced to almost undetectable levels, while mineralo- and 
glucocorticoid levels were eleveted. The CYP17A1 precursors pregnenolone and progesterone were eleveted, while 17OHP 
was slightly reduced, as were 11-deoxycortisol and cortisol, which might suggest greater effect on the hydroxylase function 
of the enzyme. DOC – deoxycorticosterone, 17OHP – 17-hydroxyprogesterone, DHEA – dehydroepiandrosterone. *=P<0.05, 
**=P<0.01, ***=P<0.005, signification compares the spesific steroid of intrest in siRNA-I and siRNA-II to the scramble 
control steroid of intrest. N=3 Results shown as Mean±SEM. 
 
5.3.3 CYP21A2 Knockdown 
Some studies indicate (Attard et al., 2012, Huang et al., 2016, Udhane et al., 2016), that 
abiraterone also inhibits CYP21A2, and since CYP17A1 and CYP21A2 pathways have 
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common precursors, the knockdown effect of CYP21A2 was examined. Similar to the situation 
with CYP17A1, CYP21A2 siRNAs caused significant knockdown (Figure 5-1 B; si-I 82%, si-II 
90%, P<0.001), which should translate into an increase in androgens and a decrease in gluco- 
and mineralocorticoids, as the enzyme inhibition would result in a shift to androgen synthesis, 
as happens in 21-hydroxylase deficient patients (Turcu and Auchus, 2015).  
However, the knockdown resulted in a decrease in most but not all mineralo- and 
glucocorticoids, and androgen levels were significantly increased only with si-II. The effect on 
the steroids also differed between si-I and si-II (Figure 5-3). SiRNA-I caused, as anticipated, a 
decrease in pregnenolone, the mineralocorticoids DOC and corticosterone, and the 
glucocorticoids 11-deoxycortisol and cortisol, and 17OHP were increased by 8-10 fold 
compared to control. Noteworthy, is the 80% decrease of androstenedione. SiRNA-II, had no 
effect on pregnenolone, and its effect on the mineralocorticoids and glucocorticoids is less than 
siRNA-I. However, the androgens, DHEA and androstenedione, are increased 2-3 fold. The 
profile received indicates that although the knockdown effect was significant and above 80% 
reduction of the mRNA, the downstream effect varies. There seems to be no correlation between 
the mRNA knockdown effects to the steroid concentrations.  
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Figure 5-3: Steroidogenesis in CYP21A2 knockdown cells 
H295R cells were tranfected with siRNAs against CYP21A2 for 48h and then replaced with a medium containing 1µM FSk 
for another 24h. The natural defficiency of CYP21A2 results in a 17OHP and androgen increase and a decrease in gluco- and 
mineralocorticoids. Here 17OHP was significantly increased, and the same is true for the mineralo- and glucocorticoids, 
except of 11-deoxycortisol that was not effected with siRNA3. The androgens were increased with the siRNA3 knocdown, 
but reduced when cells were treated with siRNA2. However no compensetion by other steroids could be detected. 
Progesterone was not detectable in the control, but both knockdowns increased it significantly. DOC  ̶ deoxycorticosterone, 
17OHP   ̶17-hydroxyprogesterone, DHEA  ̶ dehydroepiandrosterone. *=P<0.05, **=P<0.01, ***=P<0.005, signification 
compares the spesific steroid of intrest in siRNA-I and siRNA-II to the scramble control steroid of intrest. N=3 Mean±SEM. 
N.D – none detected 
 
5.3.4 POR Knockdown 
No alternative pathway steroids were detected when knocking down either CYP17A1 or 
CYP21A2, as the steroids shifted between the androgen and glucocorticoid steroidogenesis 
pathways. POR is needed for the function of both enzymes (Miller, 2005). The assumption 
was that by inhibiting POR and mimicking a known disease, and the iatrogenic condition 
caused by abiraterone treatment, there will be a detectable shift toward the alternative 
pathway. The mRNA knockdown was effective, as with the other siRNAs. Yet in this case the 
siRNA-II effect had high variability (Figure 5-1 Right; si-I 91.2% P<0.001, si-II 56.6%, 
P<0.05). The steroid analysis indicated that CYP21A2 is less sensitive to the decrease in 
POR. The knockdown did cause a significant rise of 17OHP, and DHEA was decreased by 
both siRNAs. The other steroids were either unaffected or the effect varied, as can be seen in 
androsterone, pregnenolone, DOC and corticosterone that were down regulated by one siRNA 
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and elevated or not affected by the other (Figure 5-4). Nonetheless, no alternative pathway 
steroids were detected.  
 
 
 
 
 
 
 
 
Figure 5-4: Steroidogenesis in POR knockdown cells 
H295R cells were transfected with siRNAs against POR for 48h and then replaced with a medium containing 1µM FSk for 
another 24h. POR is electrone transferase needed for the function of both CYP17A1 and CYP21A2, therefore its knockdown 
should be equivalent to double knockdown of those genes. Results indcate that CYP17A1 is more sensetive than CYP21A2 
to the POR knockdown, as the androgens were more affected than the mineralo- or glucocorticoids, which are CYP21A2 
products.  
DOC   ̶deoxycorticosterone, 17OHP  ̶ 17-hydroxyprogesterone, DHEA  ̶ dehydroepiandrosterone. *=P<0.05, **=P<0.01, 
***=P<0.005, signification compares the spesific steroid of intrest in siRNA-I and siRNA-II to the scramble control steroid 
of intrest. N=3 Mean±SEM. 
5.4 Summary 
The NCI-H295R cell line was treated with siRNAs in an attempt to mimic the effect of 
abiraterone on the adrenal gland as shown by Attard and colleagues (Attard et al., 2012). Short 
interfering RNAs were used to knockdown CYP17A1, CYP21A2 and POR. The aim was to 
investigate the possibility that the resistance of prostate cancer tumour in patients treated with 
abiraterone that inhibits CYP17A1 body-wide, is a result of the bypassing of the obstruction, 
most likely in the adrenal gland, and shifting to an alternative pathway (Attard et al., 2012, Arlt 
et al., 2004). The siRNAs achieved good knockdown, of more than 80%. However, no 
alternative pathway steroids could be detected, although the alteration in steroid profiles 
indicated the knockdown affected steroidogenesis. There are several possible reasons for the 
failure to detect the alternative pathway steroids. It is possible that residual enzymatic activity 
prevented the shift. Since no Western blots were performed, this option cannot be ruled out. 
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This option is also supported by the steroidogenesis results. The experiment was performed 
without the addition of external steroids (precursors), and it is possible that a shift did occur but 
the concentrations were too low for detection. It is possible that a longer incubation time is 
required, to eliminate residual enzymatic activity, although stable or chronic knockdowns 
should be considered. 
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6.0 Steroidogenesis in Ovarian Cancer Cell Lines  
6.1 Introduction 
Ovarian cancer (OC) is one of the most lethal cancers in women (Ferlay et al., 2010, Prat and 
Oncology, 2014, Cancer research UK, 2014c). The ovaries contain an endocrine tissue, the 
follicles stored in the cortex, responsible for the synthesis and secretion of the female sex 
hormones, progesterone, oestrone and oestradiol. This project’s aim was to investigate whether 
ovarian cancer tumours have steroidogenesis capabilities using cell lines representing four types 
of cancer, low grade serous (OAW42), high grade serous (CaOv-3), a granulosa cells tumour 
(COV434) and a possible endometrioid cancer (A2780). The aim of the study was to define the 
steroidogenesis capabilities of the different types of ovarian cell lines, representing different 
sources and types of ovarian cancer, as there is no previous data available in the area. The 
hypothesis driving the study was that the steroidogenesis in OC might be of use for early 
detection.   
6.2 Methods  
6.2.1 Cell Culture 
After cells were detached as described in the general methods section (section 3.5), cells were 
seeded in 6-well plates. COV434 cells were seeded 1.5x106 cells/well and the other cell lines, 
CaOv-3, A2780 and AOW42, at 5x105 cells/well, and were allowed to attach overnight. 
Concentrations were decided based on confluence experiments; the cells were seeded at 
different concentrations for 96h to determine the cell concentration that will give the best 
confluence for the duration of an experiment. After the attachment period all the media were 
replaced with a phenol-red free version of the growth medium, including the relevant 
supplements as described previously (section 3.0) and 1µM forskolin (FSK) was added while 
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control wells had only medium. In the steroid conversion experiments, no FSK was used. Cells 
were treated with androstenedione, pregnenolone or 17OHP at 500nM, or medium alone as 
control. Cells were incubated at 37º with 5% CO2 for 72 hours.  
6.2.2 Quantitative PCR 
Gene expression was analysed in the base line experiments, using the method described in the 
general methods section 3.2.3. The housekeeping gene was RPLP0, chosen following a 
recommendation from a colleague, Doctor Lorna Gilligan from the Institute of Metabolism and 
Systems Research at the University of Birmingham, in view of the fact GAPDH and HPRT1 
that were used for the adrenal cells are not suitable for the ovarian cells (Jacob et al., 2013, Li 
et al., 2009, Sadek et al., 2012). RPLP0 was recommended due to its Ct values and repetitive 
results both in cell lines and primary cells.  The target genes were chosen due to their function 
in the steroidogenesis (Table 3).  
Table 3: The genes used for qPCR analysis of ovarian cell lines steroidogenesis.  
Gene name Enzyme Catalogue 
number 
RPLP0 Ribosomal protein, large, P0  4310879E 
CYP11A1 Cytochrome P450 family 11 subfamily A member 1  Hs00167986 
HSD3β1 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 
Hs04194787 
HSD3β2 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 2 
Hs00605123 
CYP17A1 Cytochrome P450 family 17 subfamily A member 1 Hs01124136 
CYP21A2 Cytochrome P450 family 21 subfamily A member 2 Hs00416901 
CYP11B1 Cytochrome P450 family 11 subfamily B member 1 Hs01596404 
CYP11B2 Cytochrome P450 family 11 subfamily B member 2 Hs00167984 
17βHSD1 Hydroxysteroid (17-beta) dehydrogenase 1 Hs00166219 
17βHSD2 Hydroxysteroid (17-beta) dehydrogenase 2 Hs00157993 
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Table 3 (cont.): The genes used for qPCR analysis of ovarian cell lines steroidogenesis. 
Gene name Enzyme Catalogue 
number 
17βHSD3 Hydroxysteroid (17-beta) dehydrogenase 3 Hs00970002 
17βHSD4 Hydroxysteroid (17-beta) dehydrogenase 4 Hs00264973 
AKR1C3 Aldo-keto reductase family 1, member C3 Hs00366267 
SRD5A1 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 1) 
Hs00602694 
SRD5A2 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 2) 
Hs001658543 
CYP19A1 Cytochrome P450 family 19 subfamily A member 1 (aromatase) Hs00903413 
STS Steroid sulfatase (microsomal), isozyme S Hs00165853 
SULT1E1 Sulfotransferase family 1E member 1 Hs0096094 
ERα (ESR1) Oestrogen receptor 1 Hs00174860 
ERβ (ESR2) Oestrogen receptor 2 Hs00230957 
AR Androgen receptor Hs00171172 
PGR Progesterone receptor (PR) Hs01556702 
GPER1 G Protein-coupled oestrogen receptor 1 Hs00173506 
FSHR Follicle stimulating hormone receptor Hs00174865 
LHCGR Luteinizing hormone/choriogonadotropin receptor  Hs00174885 
NR3C2 (MR) Nuclear receptor subfamily 3 group C member 2 Hs00230906 
NR3C1 (GR) Nuclear receptor subfamily 3 group C member 1 Hs00353740 
6.2.3 Steroid Conversion  
A2780 ovarian cancer cells were exposed to three concentrations of steroids, 200nM, 500nM 
and 1000nM, for 24-96h. After initial analysis, it was decided to continue with 500nM for 72h 
for future experiments. This combination was chosen because it was the first to allow 
measurement of all the converted steroids. Three steroids were examined: pregnenolone ̶  the 
first steroid synthesised from cholesterol, 17OHP  ̶ a gateway steroid, an important steroid that 
can be converted to androgens (classic and alternative), mineralo- or glucocorticoids. The last 
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steroid tested was androstenedione  ̶  which can be converted to testosterone, and both of them 
can be aromatised, which enables the examination of the aromatisation capabilities of the cell 
lines.   
6.3 Results  
6.3.1 Baseline Steroidogenesis  
In this set of experiments, ovarian cells were seeded and treated with media with or without 
1µM FSK in order to investigate their steroidogenesis (Figure 6-1). No significant FSK effect 
could be detected. Although gene expression indicated that cells have the ability to synthesise 
steroids, none could be detected.  
6.3.1.1 A2780 Cell Line  
The cell line was derived from an endometrioid tumour (Anglesio et al., 2013). Gene 
expression analysis (Figure 6-1) revealed that the cells have CYP11A1, although in low levels, 
suggesting the cells should be able to synthesise steroids de novo. However, they lack HSD3B 
enzymes, and therefore can only synthesise Δ4 steroids (pregnenolone, 17OHPreg, DHEA and 
androstenediol). The qPCR results also showed that the FSK did not affected the cells gene 
expression (data not shown).  
6.3.1.2 OAW42 Cell Line 
The cell line is considered to be of low grade serous type and likely to be of Fallopian tube 
origin (Li et al., 2011). Gene expression revealed CYP11A1 in relatively high levels (Figure 
6-1). It has HSD3B1 but not HSD3B2 or CYP17A1. According to the gene expression, these 
cells have the mRNA required to express CYP19A1 (aromatase) which aromatise 
androstenedione and testosterone.  
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6.3.1.3 CaOv-3 Cell Line 
This high grade serous cell line, derived from a tumour originated in the Fallopian tube (Perets 
et al., 2013), expresses all the genes needed to synthesis oestrogens de novo (Figure 6-1), 
CYP11A1, CYP17A2, HSD3B2, 17BHSD1 and CYP19A1.  
6.3.1.1 COV434 Cell Line 
A granulosa cell line (Public Health England, Zhang et al., 2000, van den Berg-Bakker et al., 
1993) is the only cell line originated from cells that are known to have steroidogenesis function. 
The gene expression (Figure 6-1) indicates the cells have the potential to synthesise oestrogens 
when given pregnenolone or other downstream steroids, as they lack CYP11A1.  
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Figure 6-1: Steroidogenic gene expression in 4 ovarian cancer cells 
Ovarian cell lines were examined for steroidogenesis potential at 72h. The cells have different gene profiles, which could be 
expected since they originate from different tissues. However, they have some common traits, no expression of CYP11B1, 
CYP11B2 that synthesis mineralocorticoids and no HSD17B4. All of the cell lines express HSD17B3, which is normally 
expressed only in the testis, CYP21A2, SRD5A1, AKR1C3, CYP19A1, SULT1E1 and STS the last three are related to the 
oestrogen synthesis. The results indicate that the cells, including the granulosa cell line, cannot synthesis steroids de novo but 
can utilise precursors to synthesis oestrogens. Housekeeping gene was RPLP0 (Ribosomal protein, large, P0). Results shown 
as Mean±SEM, A2780 N=3, except SRD5A2 N=1, CaOv-3 N=2, except SRD5A2 N=1, COV434 and OAW42 N=1.  
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6.3.2 Ovarian Cancer Cells’ Receptor Expression  
 The expression levels of the receptors for LH (LHCGR), FSH (FSHR) and several steroids 
were analysed. The LHCGR and FSHR mediate their ligand activity in the follicle cells, LH 
regulates androgen synthesis and FSH regulates oestrogen synthesis, yet each of the cell lines 
examined expressed only one of them, three of the cell lines expressed FSHR while CaOv-3 
expresses only LHCGR. The steroid receptors tested for were expressed in all cell line execpt 
for ESR1 (oestrogen receptor α) and PGR (progesterone receptor) which were not expressed in 
OAW42 and/or A2780. All cell lines expressed high levels of mineralo- and glucocorticoid 
receptors that are not required for ovarian steroidogenesis regulation (Figure 6-2).  
 
 
 
 
 
 
Figure 6-2: Receptor expression in ovarian cell lines 
The expression levels of LH and FSH receptors, which regulate follicular steroidogenesis, and of different steroid receptors 
were measured. The LH and FSH receptors were not expressed in all the cell lines, with the LHCGR expressed only in the 
HGS cell line CaOv-3. Each steroid receptor was expressed in all cell lines, except for two ESR1 and PGR. It is noteworthy 
that all cell lines expressed relatively high levels of mineralo- and glucocorticoid receptors, to the best of my knowledge. 
These steroids have no known physiological role in the follicles.  
LHCGR – luteinizing hormone receptor, FSHR – follicle stimulating hormone receptor, ESR – oestrogen receptor, PGER – 
G-coupled oestrogen receptor, PGR – progesterone receptor, MR – mineralocorticoid receptor, GR – glucocorticoid receptor, 
AR – androgen receptor. Results shown as mean±SEM, N=3  
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6.3.3 Steroid Conversion in Ovarian Cells 
Following the baseline experiments, indicating that the cell lines express the genes needed for 
oestrogens synthesis, mostly through precursors, an experiment was set up to examine the 
steroidogenesis when the cells were treated with key steroid precursors. Pregnenolone, 17OHP 
or androstenedione, 500nM each, were added to the cell media and steroids were measured 
using LC-MS/MS as described before (section 3.5). The addition of pregnenolone or 17OHP, 
resulted in little to no measurable conversion in all the cell lines (Data not shown).  
6.3.3.1 A2780 Androstenedione Conversion 
When cells were co-incubated with 500nM androstenedione some downstream conversion was 
detected, as can be seen in Figure 6-3 A. Androstenedione was converted to androstanedione 
but also to andosterone which belongs to the alternative DHT biosynthesis pathway. No 
testosterone or DHT were detected, although AKR1C3 was expressed.  
6.3.3.2 OAW42 Androstenedione Conversion  
In this cell line, the androstenedione conversion resulted in both measurable testosterone and 
DHT. It seems that some of the androstenedione was converted directly to testosterone, but 
some was converted to the alternative pathway steroids androsterone and androstanediol 
(Figure 6-3 B). 
6.3.3.3 CaOv-3 Androstenedione Conversion 
Although this cell line expresses the genes to convert androstenedione to androstanedione, 
testosterone, DHT and oestrogens, only low concentrations of androstanedione were detectable 
(Figure 6-3 C). It is possible that the rest of the androstenedione was converted to oestrogens. 
However, the oestrogens levels were undetectable. 
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6.3.3.4 COV434 Androstenedione Conversion 
COV434 cells express all the genes needed for oestrogens synthesis when given pregnenolone 
or other steroids. Yet, only conversion to androstanedione could be detected (Figure 6-3 D). 
Oestrogens could not be measured due to low concentrations, below the LC-MS/MS level of 
sensitivity, about 30nM, it is impossible to know if any of the androstenedione was converted 
to them. 
Figure 6-3: Androstenedione conversion in ovarian cell lines  
The ovarian cell lines showed no steroidogenesis at control conditions, therefore key steroids were added to the media to 
examine their steroidogenesis, as mRNA analysis indicated they have steroidogenic genes. A2780, endomitriodic cell line 
(A), OAW42 low grade serous cell line (B), CaOv-3, high grade serous cell line (C) and COV434, granulosa cell line (D), 
were used. Five hundred nano molars androstenedione were added to the cell media and cells were allowed to grow. The 
results show conversion of the Androstenedione to the downstream steroids, up to DHT, OAW42 seems to be the most 
steroidogenic from this point, although androgen synthesis was detected, no oestrogen synthesis could be detected. The break 
in the Y axis and androstenedione is due to the high concentration of the steroid. Without it the other steroids will be too low 
to see. DHT – dihydrotestosterone. Mean±SEM. N=1  
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6.4 Summary 
The ovaries are endocrine tissues, and according to the results described above, the cell lines 
express steroidogenic genes allowing them to synthesise oestrogens either de novo or through 
precursors. No measurable steroids were detected when cells were not co-incubated with steroid 
substrate. When given 500nM of steroid precursors, pregnenolone, 17OHP and 
androstenedione, only the latter showed conversion. Detection limitation prevented the 
measuring of oestrogens in the cells, and the fact that only free steroids, and not modified, were 
measured may explain why less than 500nM of metabolites were detected. 
Although OC cell lines are derived from different sources and only one of the cell lines used, 
COV434, was derived from a steroidogenic cells (granulosa), yet all cell lines expressed steroid 
enzymes and under stimulation produced detectable levels of androgens from both classic and 
alternative pathways. As no non-cancerous cells were available, the question arises as to 
whether this steroidogenic capability is cancer related or not. If so, could it be used for early 
cancer detection? If the OC tumours secret steroids the increase in steroid concentrations could 
be measured in the blood or urine and assist with early detection.  
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7.0 Discussion and Conclusions / Future Directions 
7.1 Discussion and Conclusion 
Steroid hormones are essential for body development and function, being responsible for 
regulating blood pressure, metabolism, the inflammatory response, brain and reproductive 
system function, pregnancy and birth (Williams and Williams, 2003, Booth et al., 2002, 
Odermatt and Klusonova, 2015, Liggins, 1994, Miller, 2015, Walters, 2015). 
 
In this project, the steroidogenesis in cell lines derived from two cancers was examined. 
Adrenocortical carcinoma is a cancer that can secrete steroids (Else et al., 2014, Allolio and 
Fassnacht, 2006). Ovarian cancer is a cancer of an endocrine tissue, and research showed that 
its growth might be affected by steroids. Progesterone through progesterone receptor type B 
(PR-B) has a positive effect, but it is not clear if oestrogens have pro- or anti- proliferative affect 
(Diep et al., 2015, Wimalasena et al., 1992, Li et al., 2014, Jeon et al., 2016). Its growth might 
be FSH and/or LH dependent (Mertens-Walker et al., 2012, Wimalasena et al., 1992, Choi et 
al., 2007), and although these specific hormones are not steroids they regulate follicular 
steroidogenesis. 
The growth of other cancers such as prostate, discussed in the introduction, breast and uterine 
are known to be affected by steroids (Diep et al., 2015, Capper et al., 2016). With the progress 
in cancer research other cancers may in future be found to be steroid sensitive. 
During the study I examined the role of steroidogenesis in ovarian cancer and examined a 
hypothesis regarding the role of the adrenal gland in the development of castration resistant 
prostate cancer, and characterised three adrenocortical carcinoma cell lines derived from 
H295R cell line from Dr William Rainey’s laboratory.  
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In the first section, the H295R strains S1, S2 and S3 were characterised for their steroidogenic 
capabilities, and the results indicate that all three cell lines can synthesise mineralocorticoids, 
glucocorticoids and androgens, although gene expression and steroid concentrations vary 
between the cell lines. Since the cell lines were derived from the same parent cell line it is 
logical to assume that growth media supplements play a role in the steroidogenesis capabilities 
of the cells (Wang and Rainey, 2012). On one occasion, alternative DHT biosynthesis pathway 
steroids could be detected in H295R-S2 and -S3 that were treated with growth media alone. 
Those results support the data collected by Attard and colleagues (Attard et al., 2008), 
suggesting that the adrenal glands might be the source for androgen in abiraterone treated 
patients. The alternative pathway steroids were synthesised without external manipulation, and 
therefore might indicate that the adrenal glands have a role in the development of androgen 
dependent conditions such as polycystic ovary and prostate cancer. Literature search did not 
reveal any direct link between the alternative pathway androgens and the growth of CRPC. 
However, based on neonatal study (Fluck et al., 2011) it is possible to assume that the 
steroidogenic tissue in males can utilise those steroids as DHT precursors. Moreover, it was 
shown in controls and patients of polycystic ovary syndrome study that they secrete alternative 
pathway androgens and also that there is a correlation between them and the DHT levels (Saito 
et al., 2016). A congenital adrenal hyperplasia study (Kamrath et al., 2012) also demonstrated 
that alternative pathway androgens can be measured in controls and at higher levels in patients 
from both sexes, therefore it is logical to assume that a similar thing occurs in males, both 
healthy and with prostate cancer. It is difficult to compare results to other studies due to the 
different techniques, however the alternative pathway steroid concentrations measured are 
similar to the “classic” pathway steroids measured in those cells (Figure 4-3 B and C, Figure 4-
4), therefore it is possible to assume that the adrenal cells secrete high concentrations of those 
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steroids. It is difficult to determine why the alternative steroids were detected only in one 
experiment out of four performed. Yet, several options are possible, the steroid concentrations 
are actually lower and the experiment that they were measured in is the anomaly; it is also 
possible that extraction or detection problems were responsible for the lack of detection, 
especially if the steroid concentrations were low. Lack of internal standards for those steroids 
make it hard to determine the reason for this situation. Future analysis is needed in order to 
determine if the H295R cell lines can serve as model for alternative DHT biosynthesis pathway 
inhibitors. To the best of my knowledge this is the first time the steroidogenesis of those adrenal 
cell lines is characterised both by genetics and by steroid levels in those cell lines. In literature 
it is possible to find steroid analysis, mostly from patients (Kamrath et al., 2012, Saito et al., 
2016, Auchus, 2004) but not complete analysis that includes genes and steroids nor one that 
includes all the steroids in the pathway. Due to methodology differences it is not possible to 
compare the published data with the data gathered in this study. The active field of adrenal 
steroidogenesis research requires cell lines that mimic the adrenal physiology and pathology 
(Wang and Rainey, 2012). These cells can serve as adrenal steroidogenic models, synthesising 
mineralocorticoids, glucocorticoids and androgen precursors, adding to the research 
armamentarium. They may also serve as models for the study of the alternative DHT 
biosynthesis pathway, and might help in the understanding of androgen excess conditions. 
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Figure 0-1: A suggested pathway showing how adrenal androgens can affect CRPC cell growth 
A possible explanation to how alternative androgens from the adrenal glands can cause CRPC cells to grow. The adrenal 
gland synthesis androgens through the alternative pathway, those steroids are secreted to the blood stream and reach the 
prostate cancer cells were it metabolite to DHT. This pathway, based on a clinical study al., 2008), and the results shown in 
this thesis about the possibility that the adrenal can synthesis androgens even under CYP17A1 inhibition. This pathway 
suggestion need to be examined in the future. 
 
In the second section, based on the results of a clinical trial (Attard et al., 2012) H295R1 cells 
were used in knockdown experiments using siRNAs against CYP17A1, CYP21A2 and POR. 
These experiments were part of a project designed to investigate if alternative pathway steroids 
from the adrenals could be converted to DHT in the prostate cancer cells (Figure 7-1). The 
siRNAs caused a significant knockdown of the target genes which manifested in steroid 
concentrations. The steroidogenesis did not correspond, however, with the hypothesised effect 
based on known human diseases (Arlt et al., 2004, Conference, 1968, Turcu and Auchus, 2015, 
Miller and Auchus, 2011). The results might be explained based on residual gene expression, 
and since proteins were not measured, residual protein activity cannot be ignored. Moreover, in 
CYP21A2 and POR knockdowns, the differing siRNAs produced different results. This could 
indicate a non-specific binding as has been suspected in the CYP21A2 knockdown, in an attempt 
to explain the decrease in androgen with siRNA-I, or residual enzymatic activity because of 
protein turnover time. This could explain both situations (Figure 7-2). Moreover, in an 
experiment performed by Dr Hofland previously from the Arlt group in the University of 
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Birmingham, H295R1 cells were exposed to abiraterone but no alternative pathway androgens 
could be detected. On the other hand preliminary results with the VCaP prostate cancer cell line 
transplanted into orchidectomised mice and treated with abiraterone did show detectable 
concentrations of alternative steroids. The hypothesis that abiraterone treatment (CYP17A1 
inhibitor) caused a shift towards the alternative DHT biosynthesis pathway androgens could not 
be confirmed. Data not shown here hinted that the shift occurred but at very low concentrations 
and sporadic measurements prevented the data from being reliable.  
Figure 7-2: Summary of steroidogenesis due to siRNAs knockdown 
Knockdown of CYP17A1 (A) and CYP21A2 (B) affected the steroid concentrations of precursors and products of the 
knockdown enzymes. The CYP17A1 knockdown caused a decrease of the enzyme metabolites and increased its precursors. 
The CYP21A2 knockdown affect the cells in less conclusive, as the androgens downstream to the enzyme were affected 
differently by the siRNAs. Orange arrows indicate effect direction, horizontal arrow effect not clear.  
The third section examined ovarian cancer cell line steroidogenesis. The aim was to examine 
whether tumour steroidogenesis can be used for early cancer detection. Ovarian cancer has no 
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distinctive signs and is usually detected in late stages (Howlader N, 2014, SEER program, 
2011), resulting in low survival rates (Siegel et al., 2015). All the cell lines, three of them 
(A2780, OAW42 and CaOv-3) from non-steroidogenic tissues, expressed steroidogenic 
enzymes enabling them to synthesise different steroids when given precursors and all expressed 
the genes needed for oestrogenesis from androstenedione. Nonetheless, LC-MS/MS analysis 
did not detect any steroids without the addition of precursors, probably since the steroid 
concentrations were below the detection limit of the LC/MS-MS system that was used. Since 
addition of precursors did result in detectable androgen synthesis it is possible to assume that 
the cells are not capable of synthesising high concentration of the steroids de novo, yet no 
literature could be found to determine if this assumption is correct or not. Moreover, and as 
mentioned before, steroidogenesis is not usually examined in ovarian cancer cells Oestrogens  
are measured in picograms (Xu and Veenstra, 2012) and the  lower detection limit of the 
technique used is 30nM.In order to measure the oestrogen a different extraction technique is 
required and there will be a need for larger amount of cells, possibly tens of millions.  When 
cells were given precursors (pregnenolone, 17OHP and androstenedione), only downstream 
conversion products of androstenedione were measured. The measurements of pregnenolone 
and 17OHP could not be properly analysed due to a probable faulty batch of the extraction 
solvent, Tert-butylmethyl ether (MTBE), affecting steroid extraction, causing poor recovery. 
This acquirement of steroidogenesis capabilities might have a role in the cancer development 
and should be studied farther. The ovarian cancer cells ability to synthesise alternative DHT 
biosynthesis pathway steroids and their expression of CYP21A2, MR and GR genes mRNA are 
not, to the best of my knowledge, a feature of normal ovarian steroidogenesis. These results 
suggest that the ovarian cancer tumours become steroidogenic, able to metabolise certain 
steroids, mainly androstenedione, regardless of their tissue of origin. Although not shown in 
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this study, it can be assumed that those cell lines can synthesis oestrogens (Xu and Veenstra, 
2012, Zhang et al., 2000), which are likely pro-proliferative (Wimalasena et al., 1992, Li et al., 
2014, Jeon et al., 2016), but this is yet to be determined (Xu and Veenstra, 2012, Zhang et al., 
2000) . The change in steroidogenesis might also serve to detect cancer due to a surge or change 
in oestrogens or androgens in the blood or urine, especially of the alternative DHT biosynthesis 
pathway androgens. The alternative pathway steroids are not aromatizable, and therefore will 
not affect oestrogen production. However, depending on their levels, they could cause 
symptoms of androgen excess, especially if causing an increase in DHT. This possibility, if 
proven true, should be considered when treating women showing androgen excess symptoms. 
Those androgens, however, probably have no role in tumour growth since androgens have no 
known role in ovarian development. Therefore, those androgens are most likely to have a role 
as biomarkers for ovarian cancer rather than affecting its progress.  Their receptors expression 
pattern should be compared to that of other fast growing tissues as potential targets for specific 
chemotherapy administration. Their expression pattern might also allow for molecular 
differentiation between normal and cancerous cells. The ovarian cancer cells express either LH 
or FSH receptors. However, they did not respond to 1µM FSK treatment, that activates cAMP, 
although the FSH and LH affect the cells through cAMP and therefore direct stimulation is 
supposed to cause an increase mRNA expression of the effected genes such as CYP17A1, 
CYP19A1, CYP21A2 and the 17/3βHSD. The lack of effect might indicate that the cells are 
already expressing these genes at their limit, or that the FSK stimulation did not affect the cells 
for another reason. Both options need to be further evaluated. 
No oestrogens could be detected in the cell lines, although it was shown previously (Ren et al., 
2015, Xu and Veenstra, 2012). This was probably due to sensitivity level (detection level 30nM) 
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of the LC-MS/MS machine, or since they were modified (sulphated or glycosylated). During 
the study only free steroids were measured.  
This is the first time that ovarian cancer cells steroidogenic capabilities were examined, 
although the effects of selected steroid and their receptors were previously examined (Jonsson 
et al., 2015, Jeon et al., 2016), and the results show that this field should be further investigated. 
The results of the H295R cells suggest that H295R-S1, -S2 and S3 are good models for the 
adrenal steroidogenesis. The knockdown experiments however did not confirm the hypothesis 
that inhibition of CYP17A1 and/or CYP21A2 by abiraterone cause a shift to the alternative 
DHT biosynthesis pathway as a source for androgens.  
The experiments in these studies were performed using only cell lines derived from cancer 
tumours and therefore need to be validated and repeated in primary cells, derived from both 
healthy and malignant tissues. The use of benign tumours might also prove useful, maybe 
enabling the development of a tool to differentiate benign from malignant. No protein results 
were obtained regarding the knockdown effects, preventing the option to determine if the un 
expected results in the steroidogenesis of the knockdown cells were due to residual enzymatic 
activity or for other reasons. The LC-MS/MS used also limited the data, since its sensitivity 
levels might have limited steroid detection. Moreover, only the free form of the steroid was 
measured as representing the steroidogenesis. Yet, they are only a fraction of the total steroids 
produced. This might explain why in some cases steroids could not be detected or why there 
was difference between the concentrations measured in steroid conversion experiments.  
7.2 Future Directions  
Synthesis of alternative DHT biosynthesis pathway androgens in the adrenal cortex. 
The results of the cell lines characterisation supported by previous studies (Saito et al., 2016, 
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Kamrath et al., 2012) , indicate that the adrenal cortex is capable of synthesising the alternative 
DHT biosynthesis pathway androgens, even under basal conditions. This possibility should be 
further investigated, including at the protein level. Since steroid concentrations might be too 
low for detection the use of precursors should be considered, to increase concentrations of the 
steroids of interest and allow detection. This trait, the synthesis of alternative DHT biosynthesis 
pathway androgens, if found reliable, could serve as diagnostic and possibly therapeutic targets 
for steroid related carcinomas and also as a tool for the understanding of androgen excess 
conditions. 
Determining how abiraterone treatment causes shift toward the alternative pathway. 
Since the experiments to determine if CYP17A1 inhibition by abiraterone is sufficient to cause 
a shift towards the alternative pathway did not result in the hypnotised effect, nor CYP21A2 or 
POR inhibitions, this set of experiments should be revised and repeated. The original 
knockdown experiments did cause more than 80% reduction of relevant mRNA after 72h 
incubation, yet it did not translate to a repeated detectable steroid secretion. The repeat 
experiment should examine protein levels and the possibility that residual enzymatic activity 
affected the results. Depending on the protein levels detected a longer incubation period should 
be considered in order to achieve significant decline in enzymatic levels, hopefully to 
undetectable levels. Steroid concentrations should be take into account and the use of precursors 
for the examined enzymes might be needed to increase metabolites to detectable concentrations.        
The repeat experiment is needed to determine how the knockdown effects the enzymes levels 
and also consider the use of precursors to increase steroid concentrations to a detectable level.  
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Stable knockdown of CYP17A1, CYP21A2 and POR 
The abiraterone treatment is a long-term treatment and a resistant is developed only after several 
months (de Bono et al., 2011, Fizazi et al., 2012, Ryan et al., 2013). Knockdown experiments 
using siRNAs are very short in comparison. It is therefore possible that the shift towards the 
alternative pathway needs long inhibition of the relevant enzyme or enzymes. It is therefore 
recommended to try a stable knockdown in order to mimic the drug treatment. This technique, 
stable knockdown, might even prove to be a better model due to the long-term treatment with 
abiraterone.  
In vivo studies 
Preliminary study by Dr Hofland showed that a prostate cancer cell line xylograph in 
orchidectomised mice caused an increase in circulating alternative pathway steroids. This 
supports the hypothesis that the adrenal gland supports the prostate tumour growth in CRPC 
patients. This indicates that in vivo studies should be strongly considered. Since in vitro 
experiments were unable to detect alternative pathway steroids when cells were treated with 
siRNAs in an attempt to better understand how abiraterone inhibition causes shift towards the 
alternative pathway in patients, in vivo knockdown experiments might prove more effective. 
Literature search reveals that CYP17A1 and POR knockout mice are already in use (Liu et al., 
2005, Ribes et al., 2007) but no CYP21A2 knockout mice were found. Since each of those 
knockouts has a known human disease equivalent the knockout effects are already known. 
However, animal models will allow researchers to investigate the effect of different therapeutics 
on androgen synthesis both in the classic and alternative pathways. It is likely that double and 
perhaps triple knockout animals will be needed in order to mimic the effect of certain drugs as 
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is the case with abiraterone that inhibits CYP17A1, CYP21A2 and 3βHSD activities (Attard et 
al., 2012, Huang et al., 2016, Udhane et al., 2016, Ryan et al., 2010, O'Donnell et al., 2004).  
Congenital adrenal hyperplasia patients as clinical model for Alternative DHT 
biosynthesis pathway 
Studies with congenital adrenal hyperplasia patients should be considered favourably as those 
patients are nature created models for steroid studies and can be proven important 
armamentarium for understanding the role of alternative pathway steroids in health and 
pathologic conditions. 
Alternative DHT biosynthesis pathway androgens were already measured in patients with 
CYP21A2 or POR deficiency (Reisch et al., 2013, Arlt et al., 2004, Kamrath et al., 2012) but 
no data regarding alternative pathway in CYP17A1 deficiency patients could be found. 
CYP21A2 and POR deficiency patients might contribute to studies determining the effects and 
roles of the alternative pathway androgens in the body, including prostate cancer. Patients with 
CYP17A1 deficiency have very low to undetectable levels of androgens (Carvalho et al., 2016, 
Camats et al., 2015, Kim and Rhee, 2015), with a similar steroidogenesis profile as abiraterone 
treated prostate cancer patients, although CYP17A1 deficient patients are not castrated, as in 
both cases CYP17A1 enzyme function is impaired. Therefore, those patients could be a 
valuable model for the effects of abiraterone on CYP17A1 and alternative pathway androgens 
due to CYP17A1 inhibition. With that said, CYP17A1 deficiency is rare and the patients vary 
regarding 17-hydroxylase and 17,20 lyase deficiency combinations. Therefore it will be 
difficult to obtain a large enough patient cohort for a comparison study with abiraterone 
patients. If possible a pilot study should be conducted to investigate the effect of CYP17A1 
deficiency on alternative androgen synthesis in comparison to abiraterone. Serum samples 
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could also be used to investigate prostate cancer development when given to cells as 
supplement.    
Prostate tumour transplantation in severe combined immunodeficiency mice 
Severe combined immunodeficiency (SCID) mice may be used to determine alternative 
androgen concentrations in sera in humans by transplanting them with human adrenal cortex 
cells or tissue, as a pre-clinical stage, to calibrate and standardise measuring methods, prior to 
clinical measurements in humans. This is needed since today there is not enough data on those 
steroids to allow clinical use. The SCID mice, transplanted with prostate cancer tumours can 
serves as a model to examine how alternative androgens affect their development, utilising 
knockout and knockdown techniques to create enzymatic deficiency. These models will allow 
the determination of the role of the alternative pathway androgens in prostate cancer 
development and serve as a model for drug development targeting the alternative pathway. 
Ovarian cancer steroidogenesis  
The ovarian cancer experiments were aimed to examine the possibility that steroidogenesis can 
serve as a biomarker for early ovarian cancer detection. A similar study regarding early 
detection of ACC based on urine steroids is currently being conducted (Arlt et al., 2011). 
Results were unexpected, as it was found that tumour originating from non-steroidogenic tissue 
presented with a wide steroidogenic enzyme profile. Moreover, all the examined cell lines 
expressed mineralo- and glucocorticoid receptors, and CYP21A2. None, to my knowledge, is 
related to ovarian steroidogenesis. These results need to be further examined in primary 
tumours, and healthy tissues, and if found to be unique and common to the tumours might be 
useful in clinical practice. The fact that the cell lines have steroidogenesis capability might be 
useful for early cancer detection based on steroid concentrations in blood or urine. 
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Animal Models 
Animal models should be considered, SCID mice with CYP17A1, CYP21A2 or POR knockout, 
implanted with ovarian cancer cells will allow the investigation of the role of steroids, namely 
androgen and oestrogen in OC development. It will also allow the measurement of the 
concentration of steroids secreted by the tumours to determine if the change in steroidogenesis 
can serve as a biomarker. Steroids and steroidogenesis need to be considered as possible 
biomarkers and therapeutic targets in ovarian cancer research.      
To conclude, in this research it was shown that ovarian cancer cells have steroidogenesis 
capabilities, regardless of their origins. This fact, not reported before, should be further 
investigated as a means of detecting ovarian cancer in early stage and as pharmacological 
targets. H295R steroid secretion is affected by the media supplement used in the growth 
media, and therefore it is very important to grow the cells in their original media since change 
of supplement will probably change the results. It was also shown that adrenal cell lines are 
capable of secreting alternative androgens making them an in vitro model for alternative 
androgen studies. Alternative androgens can be found in healthy people (Kamrath et al., 
2012), and a comprehensive study is needed to be conducted in order to set a normal range 
which will enable the use of androgens to detect pathologies.  
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